annot,exactText,modality,statementType,drug1Lab,drug1Type,drug1Role,drug2Lab,drug2Type,drug2Role
urn:domeoclient:uuid:86F7591A-AA85-4DA1-B3F0-9E9E3C59DC33,"Coadministration of propoxyphene decreased the maximum plasma concentration of alprazolam by 6%, decreased clearance by 38%, and increased half-life by 58%",ncit:positive,ncit:quantitative,propoxyphene,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,alprazolam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:8CC8B83F-B503-46D7-8F88-E3FF55444A9A,"The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.",ncit:positive,ncit:quantitative,imipramine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,alprazolam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:DDD2CE83-C21C-4CDF-A573-AF83DC3C001B,"The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day",ncit:positive,ncit:quantitative,alprazolam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,desipramine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:99983117-22EC-44C0-B319-7421D245A408,"oadministration of cimetidine increased the maximum plasma concentration of alprazolam by 86%, decreased clearance by 42%, and increased half-life by 16%",ncit:positive,ncit:quantitative,alprazolam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,cimetidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:B98D2C81-CAE9-4A75-B024-CA477063FB33,"Coadministration of fluvoxamine approximately doubled the maximum plasma concentration of alprazolam, decreased clearance by 49%, increased half-life by 71%",ncit:positive,ncit:quantitative,alprazolam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,fluvoxamine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:D0AF7FBA-E64C-492E-892B-BD96F9E4F73A,"Repeat dose administration of oral voriconazole (400 mg Q12h for 1 day, then 200 mg Q12h for 8 days) increased the Cmax and AUC of sirolimus (2 mg single dose) an average of 7-fold (90% CI: 5.7, 7.5) and 11-fold (90% CI: 9.9, 12.6), respectively, in healthy male subjects",ncit:positive,ncit:quantitative,sirolimus,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,voriconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:23272978-4CA2-4AFF-953F-891602989105,"Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin",ncit:negative,ncit:quantitative,Atomoxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,acetylsalicylic acid,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:C3CE8BB5-8B89-4A7F-8A4C-C652B3FA4B0D,"Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin. Similarly, these compounds did not affect the binding of atomoxetine to human albumin",ncit:negative,ncit:quantitative,atomoxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,acetylsalicylic acid,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:E54A2D88-2E5A-4B04-9347-860D2C0348C1,"In extensive metabolizers (EMs), inhibitors of CYP2D6 (e.g., paroxetine, fluoxetine, and quinidine) increase atomoxetine steady-state plasma concentrations ",ncit:positive,ncit:Qualitative,quinidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,atomoxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:92F74E06-B05D-4A10-92CB-5E4F25E5C97C,"Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin",ncit:negative,ncit:quantitative,phenytoin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Atomoxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:F67E4FCB-EC36-462E-BD25-2F9F6629B083,"Drugs that elevate gastric pH (magnesium hydroxide/aluminum hydroxide, omeprazole) had no effect on atomoxetine hydrochloride bioavailability",ncit:negative,ncit:quantitative,atomoxetine hydrochloride,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,omeprazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:BE33F41F-8637-4B60-8324-74B5B2847E90,"Coadministration of atomoxetine hydrochloride (40 or 60 mg BID for 13 days) with desipramine, a model compound for CYP2D6 metabolized drugs (single dose of 50 mg), did not alter the pharmacokinetics of desipramine",ncit:negative,ncit:quantitative,atomoxetine hydrochloride,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,desipramine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:FC88143A-5B73-4C0F-8061-199EEE6219F6,"Coadministration of atomoxetine hydrochloride (60 mg BID for 12 days) with midazolam, a model compound for CYP3A4 metabolized drugs (single dose of 5 mg), resulted in 15% increase in AUC of midazolam",ncit:positive,ncit:quantitative,atomoxetine hydrochloride,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,midazolam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:B0F91A65-2F19-40FB-91CC-06FBD22D8B80,"Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin. Similarly, these compounds did not affect the binding of atomoxetine to human albumin",ncit:negative,ncit:quantitative,diazepam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,atomoxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:A84F1579-DC82-4AFA-AD28-9DF4C7FCD2DD,"Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin",ncit:negative,ncit:quantitative,diazepam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Atomoxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:470AFC13-A4B9-4EC4-8CBC-3916555CCB3A,"In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone",ncit:positive,ncit:quantitative,fluoxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,atomoxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:C49F27D6-1E6E-42EB-A935-8159E62675E2,"Drugs that elevate gastric pH (magnesium hydroxide/aluminum hydroxide, omeprazole) had no effect on atomoxetine hydrochloride bioavailability",ncit:negative,ncit:quantitative,atomoxetine hydrochloride,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,magnesium hydroxide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:ED0B2D61-41EE-4E33-A80D-F407BE9137AC,"Drugs that elevate gastric pH (magnesium hydroxide/aluminum hydroxide, omeprazole) had no effect on atomoxetine hydrochloride bioavailability",ncit:negative,ncit:quantitative,atomoxetine hydrochloride,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,atomoxetine hydrochloride,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:195A5927-AACB-4731-8E5D-ED4DA40E23EC,"Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin. Similarly, these compounds did not affect the binding of atomoxetine to human albumin",ncit:negative,ncit:quantitative,atomoxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,warfarin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:FEA76823-5957-4178-8EF7-D13383315C46,"Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin. Similarly, these compounds did not affect the binding of atomoxetine to human albumin",ncit:negative,ncit:quantitative,phenytoin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,atomoxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:3B8AFE9A-43DE-4FC5-B40D-3227A63D2051,"In extensive metabolizers (EMs), inhibitors of CYP2D6 (e.g., paroxetine, fluoxetine, and quinidine) increase atomoxetine steady-state plasma concentrations ",ncit:positive,ncit:Qualitative,paroxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,atomoxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:ABB3CBD4-30E2-4374-B27F-6CDEE2E0B0C7,"In extensive metabolizers (EMs), inhibitors of CYP2D6 (e.g., paroxetine, fluoxetine, and quinidine) increase atomoxetine steady-state plasma concentrations ",ncit:positive,ncit:Qualitative,fluoxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,atomoxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:BB68787E-9135-4F20-80D0-763C54301178,"In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone",ncit:positive,ncit:quantitative,atomoxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,paroxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:1F27B792-56F4-43B6-8A55-886A00A878E1,"Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin",ncit:negative,ncit:quantitative,Atomoxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,warfarin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:124F4F1C-9A78-432F-A5B8-6E514F2216FD,study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction,ncit:negative,ncit:quantitative,fluvoxamine maleate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,lorazepam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:1A7177B8-E86C-491C-9943-007B9085DC40,Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine,ncit:positive,ncit:Qualitative,fluvoxamine maleate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,carbamazepine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:0B4D7315-F2D2-4AC3-A2CE-03D92A95CC71," Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.",ncit:positive,ncit:Qualitative,fluvoxamine maleate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,amitriptyline,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:400FC080-F9BC-4A0E-A679-8608A4F166B8,Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other,ncit:negative,ncit:quantitative,ethanol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,fluvoxamine maleate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:80E432C7-E7FB-4149-9590-07AD7A77C23C,"Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.",ncit:positive,ncit:Qualitative,imipramine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,fluvoxamine maleate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:ADD55E8D-31DB-4CC0-9351-F93A99D3F3F8,Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol,ncit:negative,ncit:quantitative,atenolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,fluvoxamine maleate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:C1899C90-C8AC-470E-9F2B-2B3F526F7910,Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations,ncit:positive,ncit:quantitative,propranolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,fluvoxamine maleate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:45D296BA-EB30-499F-81BD-36E67CCD04F5,Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin,ncit:negative,ncit:quantitative,fluvoxamine maleate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,digoxin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:BDB2289A-D673-47F0-9DD1-3753A8E17D3E,"In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone",ncit:positive,ncit:quantitative,tacrine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,fluvoxamine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:A9C338D5-26C6-42B0-B64E-79AFA3F8CA9E, study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction. ,ncit:negative,ncit:quantitative,fluvoxamine maleate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,lorazepam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:C8317346-BFDB-4B7D-B357-1C93E2783A02,"Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine",ncit:positive,ncit:Qualitative,fluvoxamine maleate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,clomipramine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:3F64F74C-AE59-4CEC-B14A-72698E155625,Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other,ncit:negative,ncit:quantitative,ethanol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,fluvoxamine maleate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:A130E2F4-1B2B-4520-8076-7739FEA5A267,"SEPTRA may inhibit the hepatic metabolism of phenytoin. SEPTRA, given at a common clinical dosage, increased the phenytoin half-life by 39% and decreased the phenytoin metabolic clearance rate by 27%",ncit:positive,ncit:quantitative,SEPTRA,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,phenytoin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:BDE8DAA7-CFC9-414A-977C-5414A5254EFF,Coadministration of tacrine with theophylline increased theophylline elimination half-life and average plasma theophylline concentrations by approximately 2-fold,ncit:positive,ncit:quantitative,theophylline,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,tacrine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:8ACB4AC6-C421-428F-A7BB-2693845B75C4,Administration of 40 mg/day citalopram for 22 days resulted in a two-fold increase in the plasma levels of the beta-adrenergic blocker metoprolol,ncit:positive,ncit:quantitative,metoprolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,citalopram,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:3710AA20-0A1C-41E6-BC79-4C07D152BE57,"Combined administration of citalopram (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram.",ncit:positive,ncit:quantitative,citalopram,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,ketoconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:0E6CB0B2-AC50-4994-81ED-5877B17FD8BB,"Combined administration of citalopram (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram",ncit:negative,ncit:quantitative,citalopram,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,citalopram,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:FEDEB83B-6FB7-441B-B008-ACDD0D1C199B,"Second, co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone",ncit:positive,ncit:Qualitative,carbamazepine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,risperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:6A3B782E-C1C0-4A8D-9224-490141AE9FA3,"Second, co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone",ncit:positive,ncit:Qualitative,carbamazepine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,9-hydroxyrisperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:6717E018-A211-4D2F-BFCB-0BD1E6D31B2F,"High therapeutic concentrations of sulfamethazine (100 mcg/mL), warfarin (10 mcg/mL), and carbamazepine (10 mcg/mL) caused only a slight increase in the free fraction of risperidone at 10 ng/mL and 9-hydroxyrisperidone at 50 ng/mL, changes of unknown clinical significance",ncit:positive,ncit:Qualitative,warfarin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,9-hydroxyrisperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:66E63F59-01D8-4F99-B863-69D09C605C9E,"High therapeutic concentrations of sulfamethazine (100 mcg/mL), warfarin (10 mcg/mL), and carbamazepine (10 mcg/mL) caused only a slight increase in the free fraction of risperidone at 10 ng/mL and 9-hydroxyrisperidone at 50 ng/mL, changes of unknown clinical significance",ncit:positive,ncit:Qualitative,carbamazepine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,risperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:EE416896-3CDA-4025-924D-5FD241E0C0C0,"Second, co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone",ncit:positive,ncit:Qualitative,risperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,phenytoin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:C1D52AEC-44AB-4687-9838-96AB427E0843,"Second, co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone",ncit:positive,ncit:Qualitative,9-hydroxyrisperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction,phenytoin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:F56C421E-1184-41B3-A8E0-0532A706A6E4,"Second, co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone",ncit:positive,ncit:Qualitative,9-hydroxyrisperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction,phenytoin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:82DB63CF-BA61-4869-B88E-6C68FA2B88F4,"Second, co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone",ncit:positive,ncit:Qualitative,risperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,phenytoin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:4C08C12D-4CFD-4706-BFFC-3F0B2BB74018,"Second, co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone",ncit:positive,ncit:Qualitative,9-hydroxyrisperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction,carbamazepine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:374B8D0E-7B7E-42C3-9739-9F7DFC56C29E,"High therapeutic concentrations of sulfamethazine (100 mcg/mL), warfarin (10 mcg/mL), and carbamazepine (10 mcg/mL) caused only a slight increase in the free fraction of risperidone at 10 ng/mL and 9-hydroxyrisperidone at 50 ng/mL, changes of unknown clinical significance",ncit:positive,ncit:Qualitative,risperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,warfarin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:1444713A-9E23-4B06-A054-B71688EC5B2D,"High therapeutic concentrations of sulfamethazine (100 mcg/mL), warfarin (10 mcg/mL), and carbamazepine (10 mcg/mL) caused only a slight increase in the free fraction of risperidone at 10 ng/mL and 9-hydroxyrisperidone at 50 ng/mL, changes of unknown clinical significance",ncit:positive,ncit:Qualitative,9-hydroxyrisperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction,sulfamethazine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:A6379833-7F76-48EF-BA95-BB859292A72E,"Second, co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone",ncit:positive,ncit:Qualitative,phenobarbital,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,risperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:ACD2DE3C-F764-40DF-B93C-59F5ECE3039F,"Second, co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone",ncit:positive,ncit:Qualitative,rifampin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,risperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:B09A134A-7A9A-4232-A57C-BFD1F452CAFF,"Second, co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone",ncit:positive,ncit:Qualitative,9-hydroxyrisperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction,phenobarbital,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:6AC3CD80-29D0-4934-A409-F11DC425E103,"Second, co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone",ncit:positive,ncit:Qualitative,risperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,rifampin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:E34F1F7F-BADD-43A8-85ED-B2242B19CCBC,"High therapeutic concentrations of sulfamethazine (100 mcg/mL), warfarin (10 mcg/mL), and carbamazepine (10 mcg/mL) caused only a slight increase in the free fraction of risperidone at 10 ng/mL and 9-hydroxyrisperidone at 50 ng/mL, changes of unknown clinical significance",ncit:positive,ncit:Qualitative,sulfamethazine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,risperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:E9785CB1-D116-40C9-877D-E68559D658ED,"Second, co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone",ncit:positive,ncit:Qualitative,9-hydroxyrisperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction,rifampin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:8A2FB68A-8038-401C-B94A-D1482240C46F,"High therapeutic concentrations of sulfamethazine (100 mcg/mL), warfarin (10 mcg/mL), and carbamazepine (10 mcg/mL) caused only a slight increase in the free fraction of risperidone at 10 ng/mL and 9-hydroxyrisperidone at 50 ng/mL, changes of unknown clinical significance",ncit:positive,ncit:Qualitative,carbamazepine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,9-hydroxyrisperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:FC304158-73BB-439E-9DF5-3A8D97A9B58F,"Second, co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone",ncit:positive,ncit:Qualitative,risperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,carbamazepine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:2D033C51-8378-423C-ABB8-AB8BF959DE6F,"Administration of 40 mg/day citalopram for 21 days did not affect the pharmacokinetics of warfarin, a CYP3A4 substrate",ncit:negative,ncit:quantitative,warfarin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,citalopram,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:A96284AF-827C-453E-8ADA-1DAF62A30132,Citalopram did not alter the mean AUC or Cmax of pimozide,ncit:negative,ncit:quantitative,Citalopram,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,pimozide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:2C0B393C-48CD-4ECB-8F99-E4326F861D11,"In subjects who had received 21 days of 40 mg/day citalopram, combined administration of citalopram and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin",ncit:negative,ncit:quantitative,digoxin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,citalopram,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:7A4183E9-863A-4BF3-BC8F-E4BD0BB0EE78,"In subjects who had received 21 days of 40 mg/day citalopram, combined administration of citalopram and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin",ncit:negative,ncit:quantitative,digoxin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,citalopram,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:335B7175-17C5-4281-8984-30EC43D1FA5D,"In subjects who had received 21 days of 40 mg/day citalopram, combined administration of 400 mg/day cimetidine for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively",ncit:positive,ncit:quantitative,citalopram,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,cimetidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:E9B05A45-F898-482F-8208-73482835B874,The plasma levels of clarithromycin and 14-hydroxy-clarithromycin were increased by the concomitant administration of omeprazole,ncit:positive,ncit:Qualitative,omeprazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,14-hydroxy-clarithromycin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:F85A98DF-901D-4C15-AA5D-DAD86993870D,The plasma levels of clarithromycin and 14-hydroxy-clarithromycin were increased by the concomitant administration of omeprazole,ncit:positive,ncit:Qualitative,omeprazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,clarithromycin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:0996BAD0-6F29-4ED4-A8AA-FBFD40C07CEA,"For clarithromycin, the mean Cmax was 10% greater, the mean Cmin was 27% greater, and the mean AUC0-8 was 15% greater when clarithromycin was administered with omeprazole than when clarithromycin was administered alone",ncit:positive,ncit:quantitative,clarithromycin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,omeprazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:6575BFF7-4C2A-42A7-A2AB-97E7625DAC01,Clarithromycin concentrations in the gastric tissue and mucus were also increased by concomitant administration of omeprazole,ncit:positive,ncit:Qualitative,Clarithromycin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,omeprazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:073BAC30-1897-4F1A-9758-22E8C1D465F3,"For clarithromycin, the mean Cmax was 10% greater, the mean Cmin was 27% greater, and the mean AUC0-8 was 15% greater when clarithromycin was administered with omeprazole than when clarithromycin was administered alone. Similar results were seen for 14-hydroxy-clarithromycin, the mean Cmax was 45% greater, the mean Cmin was 57% greater, and the mean AUC0-8 was 45% greater.",ncit:positive,ncit:quantitative,omeprazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,14-hydroxy-clarithromycin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:E310E635-54AE-4EFC-B734-5E41A53ACBD5,"Because of its profound and long lasting inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts).",ncit:positive,ncit:Qualitative,omeprazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,ketoconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:AD31E6F4-2890-432E-9750-FE8DA30CE1C8,"Omeprazole can prolong the elimination of diazepam, warfarin and phenytoin, drugs that are metabolized by oxidation in the liver.",ncit:positive,ncit:Qualitative,warfarin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Omeprazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:E35AC011-B6AD-4D8F-9A51-3B08DA613249,"Following multiple doses of atazanavir (400 mg, qd) and omeprazole (40 mg, qd, 2 hr before atazanavir), AUC was decreased by 94%, Cmax by 96%, and Cmin by 95%.",ncit:positive,ncit:quantitative,omeprazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,atazanavir,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:1B8820FF-46D7-4E2A-AC3F-B29F2C0FFA1D,"Because of its profound and long lasting inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts).",ncit:positive,ncit:Qualitative,omeprazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,ampicillin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:0C8D731D-0812-4386-8395-E70C1006EEE1,"Following multiple doses of nelfinavir (1250 mg, bid) and omeprazole (40 mg, qd), AUC was decreased by 36% and 92%, Cmax by 37% and 89% and Cmin by 39% and 75% respectively for nelfinavir and M8",ncit:positive,ncit:quantitative,omeprazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,nelfinavir,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:CE574C70-1DC6-4D50-9A06-F7FFCE6D1AAE,"Following multiple doses of nelfinavir (1250 mg, bid) and omeprazole (40 mg, qd), AUC was decreased by 36% and 92%, Cmax by 37% and 89% and Cmin by 39% and 75% respectively for nelfinavir and M8",ncit:positive,ncit:quantitative,M8,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction,omeprazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:D52971FD-B5B4-4283-A040-184E9A5DF954,"Because of its profound and long lasting inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts).",ncit:positive,ncit:Qualitative,omeprazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,iron,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:7A3FC884-11C3-41CE-A7A4-A4052DC280F3,"Omeprazole can prolong the elimination of diazepam, warfarin and phenytoin, drugs that are metabolized by oxidation in the liver.",ncit:positive,ncit:Qualitative,diazepam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Omeprazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:AEF99033-A03D-40F6-B5D0-D186A7349BAA," For some antiretroviral drugs, such as atazanavir and nelfinavir, decreased serum levels have been reported when given together with omeprazole",ncit:positive,ncit:Qualitative,atazanavir,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,omeprazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:79F22004-F740-4579-9800-133FEACD1405,Concomitant administration of omeprazole and tacrolimus may increase the serum levels of tacrolimus,ncit:positive,ncit:Qualitative,tacrolimus,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,omeprazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:07BE2289-D56D-496D-B8B0-B3F1926D7C91,"Omeprazole can prolong the elimination of diazepam, warfarin and phenytoin, drugs that are metabolized by oxidation in the liver.",ncit:positive,ncit:Qualitative,Omeprazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,phenytoin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:74A40820-C663-4653-A047-345B456EEC21,"When voriconazole (400 mg Q12h x 1 day, then 200 mg x 6 days) was given with omeprazole (40 mg once daily x 7 days) to healthy subjects, it significantly increased the steady-state Cmax and AUC0-24 of omeprazole, an average of 2 times (90% CI: 1.8, 2.6) and 4 times (90% CI: 3.3, 4.4) respectively as compared to when omeprazole was given without voriconazole",ncit:positive,ncit:quantitative,voriconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,omeprazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:CFC07CE8-DD7D-49B3-9A1D-70F992D5ADD4,"For some antiretroviral drugs, such as atazanavir and nelfinavir, decreased serum levels have been reported when given together with omeprazole",ncit:positive,ncit:Qualitative,nelfinavir,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,omeprazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:2AA5226E-E3E1-43EE-9D21-71F961325536,Concomitant administration of omeprazole and voriconazole (a combined inhibitor of CYP2C19 and CYP3A4) resulted in more than doubling of the omeprazole exposure,ncit:positive,ncit:quantitative,omeprazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,voriconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:619FC491-C4E3-45CD-A5F2-EA144F02F62A,"For other antiretroviral drugs, such as saquinavir, elevated serum levels have been reported with an increase in AUC by 82%, in Cmax by 75% and in Cmin by 106% following multiple dosing of saquinavir/ritonavir (1000/100 mg) bid for 15 days with omeprazole 40 mg qd co-administered days 11 to 15",ncit:positive,ncit:quantitative,omeprazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,saquinavir,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:0C4069DC-96BC-4691-AD45-9EF1DA24841B,"A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively",ncit:positive,ncit:quantitative,oxycodone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,rifampin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:2852E69A-F624-4313-9ACE-90B5AE985916,"A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively",ncit:positive,ncit:quantitative,oxycodone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,voriconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:5EC8BFE5-51E6-40F8-B5F9-D17941122C65,"A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, significantly decreased plasma oxycodone concentrations",ncit:positive,ncit:Qualitative,rifampin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,oxycodone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:22C37EE8-1D7E-4F8E-BDAE-F59E6A498F74,"A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone",ncit:positive,ncit:Qualitative,voriconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,oxycodone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:ACD3E3A1-6B23-4D9D-9080-7FCFB2F135E1,Administration of the antacid two hours after sotalol has no effect on the pharmacokinetics or pharmacodynamics of sotalol,ncit:negative,ncit:quantitative,antacid,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,sotalol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:C4519639-3DB2-4D7A-9073-C37A46D022E3,"Administration of sotalol within 2 hours of antacids containing aluminum oxide and magnesium hydroxide should be avoided because it may result in a reduction in Cmax and AUC of 26% and 20%, respectively and consequently in a 25% reduction in the bradycardic effect at rest.",ncit:positive,ncit:quantitative,sotalol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,antacids containing aluminum oxide and magnesium hydroxide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:7D9181A2-D928-45FE-91CC-F06FEC40D292,Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).,ncit:negative,ncit:quantitative,risperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,lithium,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:B307FCD2-4ED5-4F27-AC79-8754BBD2E920,"Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone,",ncit:positive,ncit:Qualitative,9-hydroxyrisperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction,phenytoin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:2CFF49F6-6E8A-49A7-B51A-9FF26BAA4E96,"Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.",ncit:positive,ncit:quantitative,risperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,paroxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:3A1259E4-A18A-42E6-9041-5FB141EE9535,Chronic administration of clozapine with risperidone may decrease the clearance of risperidone,ncit:positive,ncit:Qualitative,clozapine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,risperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:9D93EFBC-BF63-4E50-BCD0-2736639F1E64,"However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined",ncit:negative,ncit:quantitative,9-hydroxyrisperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction,cimetidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:6BF4A3EC-8677-4691-B613-846D26AE3F36,Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%,ncit:positive,ncit:quantitative,risperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Carbamazepine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:F91B2D0F-629B-4718-A482-6246F125AB53,"n drug interaction studies, risperidone did not significantly affect the pharmacokinetics of donepezil and galantamine, ",ncit:negative,ncit:quantitative,risperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,donepezil,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:C365C778-177F-4278-905D-F7E125902C4A,Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone,ncit:negative,ncit:quantitative,9-hydroxyrisperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction,Fluoxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:3EF1E25B-D32E-4DB0-8710-8B3A564AD5F9,"Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone,",ncit:positive,ncit:Qualitative,rifampin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,risperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:F39017BF-5B52-43F7-87D7-42A350A4FDB8,"However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone",ncit:positive,ncit:quantitative,risperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,valproate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:96C65041-BBFD-4B6D-9490-8244D9E8F3DB,"Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.",ncit:positive,ncit:quantitative,Cimetidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,risperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:A758EB82-284F-4D77-B56F-24DE6456C1B5,"Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone,",ncit:positive,ncit:Qualitative,phenobarbital,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,risperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:0FEC64AA-7E79-40CE-86DF-E473893040B5,Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined,ncit:negative,ncit:quantitative,Amitriptyline,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,9-hydroxyrisperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:34B48A15-A74C-4C39-BA43-773498788471,"Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.",ncit:positive,ncit:quantitative,risperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,ranitidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:27BEE460-B85C-4283-AAAD-EBF279054828,"n drug interaction studies, risperidone did not significantly affect the pharmacokinetics of donepezil and galantamine,",ncit:negative,ncit:quantitative,risperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,galantamine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:F82137CC-0CBA-4E20-A241-14382FAF7DFB,"Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone,",ncit:positive,ncit:Qualitative,phenobarbital,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,9-hydroxyrisperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:756BDED4-20B1-4CFF-805F-90D458C94BF7,Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%,ncit:positive,ncit:quantitative,9-hydroxyrisperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction,Carbamazepine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:06A31504-06D6-4BB4-9653-43ABE5933B67,Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21),ncit:negative,ncit:quantitative,risperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,valproate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:1E8B34A3-FF88-481D-A387-712FC2383C5B,"Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone,",ncit:positive,ncit:Qualitative,rifampin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,9-hydroxyrisperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:1144AD8C-3497-406B-9345-176B886EE315,Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%,ncit:positive,ncit:quantitative,Paroxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,9-hydroxyrisperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:6BED2958-51AA-4F41-9EEE-E7999EEA032E,Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin,ncit:negative,ncit:quantitative,digoxin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Risperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:A61E1385-D1F9-483B-909C-D9DC9265A249,Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined,ncit:negative,ncit:quantitative,Amitriptyline,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,risperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:51144278-0443-4DD0-8938-8D0C7AD740CE,whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%,ncit:positive,ncit:quantitative,9-hydroxyrisperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction,ranitidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:7664169B-C88F-4B15-B787-57A92153817B,Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%. Plasma concentrations of carbamazepine did not appear to be affected,ncit:negative,ncit:Qualitative,Carbamazepine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,risperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:A530B301-3FA4-4975-BB9B-F83FCF19E9BB,"Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.",ncit:positive,ncit:quantitative,risperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Fluoxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:6CE6D4C1-901C-4A94-BAAE-F89A836E5DF1,Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%. Plasma concentrations of carbamazepine did not appear to be affected,ncit:negative,ncit:Qualitative,carbamazepine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,9-hydroxyrisperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:229178A9-5961-401E-95BD-99051FBCC1F6,"Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone,",ncit:positive,ncit:Qualitative,risperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,phenytoin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:C5A46655-15D2-4A34-98D6-1CA4C88FC947,Nefazodone plasma concentrations were unaffected by alprazolam,ncit:negative,ncit:quantitative,Nefazodone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,alprazolam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:24032CE3-E0E5-4D93-B25B-2B5B5130A301,"When alprazolam (1 mg BID) and nefazodone (200 mg BID) were coadministered, steady-state peak concentrations, AUC and half-life values for alprazolam increased by approximately 2-fold",ncit:positive,ncit:quantitative,nefazodone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,alprazolam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:7AC452E8-5C81-487F-BEE8-26D47C1851C0,Nefazodone plasma concentrations were unaffected by triazolam,ncit:negative,ncit:quantitative,Nefazodone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,triazolam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:2F2F19BC-5675-48B7-B5B3-3BC688888927,Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels,ncit:positive,ncit:Qualitative,nisoldipine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,phenytoin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:7A03EBC4-764E-433B-A61A-1826AAD2FCDF,Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%),ncit:positive,ncit:quantitative,nisoldipine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Ranitidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:400FF6FE-F3F7-4D02-B569-2CB23F81FB0C,"Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant",ncit:negative,ncit:Qualitative,nisoldipine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,atenolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:793C8078-ADF3-4631-BEE7-9C32466DBDA6,Immediate release nisoldipine increased plasma quinidine concentrations by about 20%,ncit:positive,ncit:quantitative,Immediate release nisoldipine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,quinidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:803378AB-300A-4838-AA5C-D6B9E2424780,Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%,ncit:positive,ncit:quantitative,nisoldipine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Quinidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:AC9002B3-2126-404A-B893-895DD616687B,"Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration",ncit:negative,ncit:quantitative,nisoldipine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Quinidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:91DA3E58-26EC-499D-8815-24EC56B7DA52,"Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant",ncit:negative,ncit:Qualitative,nisoldipine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,propranolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:1B94ED49-1802-4E07-939D-F98D12878FE4,"Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant",ncit:negative,ncit:Qualitative,nisoldipine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,propranolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:02F92A5D-FB3B-44EB-9B4A-7664307523D9,"Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant",ncit:negative,ncit:Qualitative,nisoldipine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,atenolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:9805ABDB-74EB-4727-9992-01F247DDED3A,A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily,ncit:positive,ncit:quantitative,nisoldipine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,cimetidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:F08059FF-5CE0-4E71-9F41-A1016A24A8A2,Coadministration of carbamazepine with nefazodone results in insufficient plasma concentrations of nefazodone and its active metabolite to achieve a therapeutic effect,ncit:positive,ncit:Qualitative,active metabolite,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction,carbamazepine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:26FB0EC5-898A-4764-A272-64E0BAC2A868,Coadministration of carbamazepine with nefazodone results in insufficient plasma concentrations of nefazodone and its active metabolite to achieve a therapeutic effect,ncit:positive,ncit:Qualitative,carbamazepine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,nefazodone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:CDEE251A-D6DB-44C0-B8B6-B6864FACAEB7,Zonisamide single dose pharmacokinetic parameters were not affected by cimetidine (300 mg four times a day for 12 days),ncit:negative,ncit:Qualitative,cimetidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,Zonisamide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:81BB297D-F5A5-4080-934D-2CFCD554B6C1,"Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials.",ncit:negative,ncit:Qualitative,Zonisamide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,valproate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:EA833C64-85F9-4A56-8841-F6EE3F0EE474,"Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials.",ncit:negative,ncit:Qualitative,phenytoin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Zonisamide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:8AC73974-E124-44C3-976B-7D274AD71A50,"Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials.",ncit:negative,ncit:Qualitative,Zonisamide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,carbamazepine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:C0DFD5E8-187E-4E1E-9152-A7A758D286E2,"Diltiazem significantly decreases the clearance and increases the t1/2 of quinidine, but quinidine does not alter the kinetics of diltiazem",ncit:positive,ncit:Qualitative,Diltiazem,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,quinidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:6E9A5C8E-F39F-4DC2-9AA8-98D6590E9577,"Diltiazem significantly decreases the clearance and increases the t1/2 of quinidine, but quinidine does not alter the kinetics of diltiazem",ncit:negative,ncit:Qualitative,diltiazem,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,quinidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:90476DBC-20CD-4E47-9D67-14A957BE92FA,"Perhaps because of competition for the P450 3A4metabolic pathway, quinidine levels rise when ketoconazole is coadministered",ncit:positive,ncit:Qualitative,ketoconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,quinidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:C6E40223-0F43-4E64-9C23-5466E28DE5BE,Co-administration of fosamprenavir/ritonavir with paroxetine significantly decreased plasma levels of paroxetine.,ncit:positive,ncit:Qualitative,paroxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,fosamprenavir/ritonavir,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:0037D210-B236-44FC-8A66-EFB6D728EC15,"Daily oral dosing of immediate-release paroxetine (30 mg once daily) increased steady-state AUC0-24, Cmax, and Cmin values of procyclidine (5 mg oral once daily) by 35%, 37%, and 67%, respectively, compared to procyclidine alone at steady state.",ncit:positive,ncit:quantitative,paroxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,procyclidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:F8ABD1C3-2E64-4005-BA7D-EAC62495E40C,"In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged",ncit:positive,ncit:quantitative,haloperidol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,venlafaxine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:E695B70D-90FE-4BE3-A3D5-8D7A964908D0,"A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole. Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects. Cmax values for ODV increased by 14% and 29% in EM and PM subjects, respectively",ncit:positive,ncit:quantitative,ODV,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction,ketoconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:19AAB8A2-EFBD-4281-9F62-D1A80F2A36C7,"Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects",ncit:negative,ncit:quantitative,diazepam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,ODV,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:CAFC553F-EA28-4924-BE34-12C29BA840B6,"Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam",ncit:negative,ncit:quantitative,diazepam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Venlafaxine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:EEAD9028-A0AF-42B8-B2F6-3DA6DB516663,"Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19",ncit:negative,ncit:quantitative,diazepam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Venlafaxine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:604C8B72-4E70-4BA1-A1A4-F494BE54E1D6,"However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine",ncit:positive,ncit:quantitative,desipramine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,venlafaxine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:2E74A58C-BB8A-4C07-AFDA-8FFC4FB5D21B,The steady-state pharmacokinetics of venlafaxine administered at 150 mg/day were not affected when a single 600 mg oral dose of lithium was administered to 12 healthy male subjects.,ncit:negative,ncit:quantitative,lithium,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,venlafaxine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:5752E68C-38C6-45A5-84BC-D5DB4AC0BB18,"Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects. The oral clearance of venlafaxine was reduced by about 43%, and the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60%",ncit:positive,ncit:quantitative,cimetidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,venlafaxine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:C90E1110-F500-4932-87CD-B49C02A63350,"Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC. ",ncit:positive,ncit:quantitative,Venlafaxine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,risperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:96BDA936-D469-49C4-9097-138FE35B1FAE,A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects,ncit:negative,ncit:quantitative,ethanol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,O-desmethylvenlafaxine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:869A0F1A-D9DD-44E3-B809-4B7DC12C160F,A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or O-desmethylvenlafaxine (ODV) when venlafaxine was administered at 150 mg/day in 15 healthy male subjects,ncit:negative,ncit:quantitative,venlafaxine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,ethanol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:08790F02-7B6C-4F4A-A723-6FDBEF808840,Imipramine did not affect the pharmacokinetics of venlafaxine and ODV,ncit:negative,ncit:quantitative,Imipramine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,ODV,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:2D42E35D-7832-470F-9AC0-83F6938416DB,Venlafaxine had no effect on the pharmacokinetics of lithium ,ncit:negative,ncit:quantitative,lithium,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Venlafaxine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:D6637325-01EA-46B7-974E-D7876074C0E0,"This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine",ncit:negative,ncit:quantitative,venlafaxine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,diazepam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:BFB3E654-020F-40D9-98FA-D38FBC390978,The steady-state pharmacokinetics of venlafaxine administered at 150 mg/day were not affected when a single 600 mg oral dose of lithium was administered to 12 healthy male subjects. ODV also was unaffected,ncit:negative,ncit:quantitative,ODV,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction,lithium,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:8FF24619-EEED-467A-9756-59F6120D95A1,Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.,ncit:negative,ncit:quantitative,ODV,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction,Indinavir,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:E2D0BB80-FC84-4BBC-A57D-003D3FE61E11,Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine,ncit:negative,ncit:quantitative,imipramine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Venlafaxine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:29F908DE-E7F6-4FCF-A000-CE56F0B48953," In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide",ncit:negative,ncit:quantitative,4-hydroxy-tolbutamide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction,venlafaxine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:A8D31753-89FA-432B-82F8-5F358E6A4438,"Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine",ncit:negative,ncit:quantitative,venlafaxine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Metoprolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:59EEB36C-6BC9-4C74-8335-1098ECD029E1,"This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine",ncit:negative,ncit:quantitative,venlafaxine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,terfenadine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:BEDE5C95-8BD5-4B00-82E1-44F7F4150C36,The 2-OH-desipramine AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold (with venlafaxine 75 mg q12h,ncit:positive,ncit:quantitative,2-OH-desipramine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction,venlafaxine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:59248F86-03FF-4421-A362-640F8802F40C,"In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax",ncit:positive,ncit:quantitative,indinavir,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,venlafaxine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:A16BDD7B-2473-455E-9B19-0F7F353ABD1E,"Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, α-hydroxymetoprolol",ncit:positive,ncit:quantitative,metoprolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,venlafaxine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:658212CF-63DD-4072-9079-9041F059B7C7,"However, coadministration of cimetidine had no apparent effect on the pharmacokinetics of ODV, which is present in much greater quantity in the circulation than venlafaxine.",ncit:negative,ncit:quantitative,ODV,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction,cimetidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:45436929-BE1C-472C-A19D-0BFA27F0E8E0,"Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, α-hydroxymetoprolol",ncit:negative,ncit:quantitative,venlafaxine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,α-hydroxymetoprolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:61C950E9-35C7-42F6-8FDC-1A8B76951B7A,Indinavir did not affect the pharmacokinetics of venlafaxine and ODV,ncit:negative,ncit:quantitative,venlafaxine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Indinavir,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:C05134D8-D3AE-4C81-ABA2-FA48A15F9BC7," In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide",ncit:negative,ncit:quantitative,venlafaxine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,tolbutamide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:CAC4D093-BC04-4F88-9861-EB1C34BD5F97,"Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine",ncit:negative,ncit:quantitative,Metoprolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,O-desmethylvenlafaxine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:4C17B7CB-243E-4AA0-919E-524BADC2FA23,"Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam",ncit:negative,ncit:quantitative,desmethyldiazepam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction,Venlafaxine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:F0CAC4A4-4458-4BD8-BCC1-D3DDD33CB459,"Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC",ncit:positive,ncit:quantitative,Venlafaxine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,haloperidol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:2D03B027-F3B0-44B1-9BEE-0A3205E6E15F,"A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole. Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects. Cmax values for ODV increased by 14% and 29% in EM and PM subjects, respectively",ncit:positive,ncit:quantitative,Venlafaxine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,ketoconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:657A99E3-8C2E-491A-92A5-BDB4A94258E0,"However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone)",ncit:negative,ncit:quantitative,venlafaxine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,risperidone plus 9-hydroxyrisperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:327D4369-E2F7-4EB3-97D3-2D0524EF1222,Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.,ncit:negative,ncit:quantitative,Imipramine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,venlafaxine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:C9D34189-A23F-482F-9A16-02CBC28903AA,"This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine",ncit:negative,ncit:quantitative,alprazolam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,venlafaxine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:FA7CF7F2-381B-4222-98FA-3B5BF9119254,"This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate.",ncit:negative,ncit:quantitative,caffeine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,venlafaxine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:1DBBA1AC-9928-40FB-9688-617D25D6FF57,"Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects",ncit:negative,ncit:quantitative,venlafaxine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,diazepam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:1164DBEE-56BB-4015-BD09-E96AF3CCF84C,"In addition, the haloperidol Cmax increased 88% when coadministered with venlafaxine, but the haloperidol elimination half-life (t1/2) was unchanged",ncit:negative,ncit:quantitative,venlafaxine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,haloperidol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:474957B5-A91C-44C9-B21A-B903DA9BDD5F,Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine,ncit:negative,ncit:quantitative,Venlafaxine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,2-OH-imipramine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:70860C9F-FD32-4885-BB91-3C969DE62AAB,A multiple-dose study with immediate-release paroxetine hydrochloride has shown that there is no pharmacokinetic interaction between paroxetine and lithium carbonate,ncit:negative,ncit:quantitative,lithium carbonate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,paroxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:ECCC4F0E-15A4-45D7-84B2-42010269DDA8,A multiple-dose study with immediate-release paroxetine hydrochloride has shown that there is no pharmacokinetic interaction between paroxetine and lithium carbonate,ncit:negative,ncit:quantitative,lithium carbonate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,immediate-release paroxetine hydrochloride,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:76FBA95B-4989-4357-866B-E55A371AE4B1,"An in vivo interaction study involving the coadministration under steady-state conditions of paroxetine and terfenadine, a substrate for CYP3A4, revealed no effect of paroxetine on terfenadine pharmacokinetics",ncit:negative,ncit:quantitative,paroxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,terfenadine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:9F555004-907D-4CFE-B31F-B156193ABBBF,"In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold",ncit:positive,ncit:quantitative,9-hydroxyrisperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,paroxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:2189D53F-E065-4D13-8350-5F5101E3F5FF,"In 1 study, daily dosing of immediate-release paroxetine (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively",ncit:positive,ncit:quantitative,immediate-release paroxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,desipramine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:CE39D8D2-6994-44E6-85EA-06D17FD4620E,"In healthy volunteers who were extensive metabolizers of CYP2D6, paroxetine 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours. This resulted in increases in steady state atomoxetine AUC values that were 6- to 8-fold greater and in atomoxetine Cmax values that were 3- to 4-fold greater than when atomoxetine was given alone",ncit:positive,ncit:quantitative,paroxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,atomoxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:4CA5566E-C5EF-4331-9A84-9837CEB8D62E,"In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold",ncit:positive,ncit:quantitative,paroxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,risperidone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:FBC676FF-39DC-4915-8BC3-2D37A98B968C,"When a single oral 30-mg dose of immediate-release paroxetine was administered at phenytoin steady state (300 mg once daily for 14 days), paroxetine AUC and T½ were reduced (by an average of 50% and 35%, respectively) compared to immediate-release paroxetine administered alone",ncit:positive,ncit:quantitative,phenytoin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,immediate-release paroxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:F379E7EB-7A42-43A3-9BEB-B93D4364826F,"In a separate study, when a single oral 300-mg dose of phenytoin was administered at paroxetine steady state (30 mg once daily for 14 days), phenytoin AUC was slightly reduced (12% on average) compared to phenytoin administered alone.",ncit:positive,ncit:quantitative,phenytoin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,paroxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:609A35A3-EABB-4729-AC4F-B060758285B6,"When a single oral 30-mg dose of immediate-release paroxetine was administered at phenobarbital steady state (100 mg once daily for 14 days), paroxetine AUC and T½ were reduced (by an average of 25% and 38%, respectively) compared to paroxetine administered alone",ncit:positive,ncit:quantitative,immediate-release paroxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:object-drug-of-interaction,phenobarbital,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:3DE329C4-DA46-4442-9938-C8C9E165958F,"In a controlled study of healthy volunteers, after immediate-release paroxetine hydrochloride was titrated to 60 mg daily, co-administration of a single dose of 2 mg pimozide was associated with mean increases in pimozide AUC of 151% and Cmax of 62%, compared to pimozide administered alone",ncit:positive,ncit:quantitative,pimozide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,immediate-release paroxetine hydrochloride,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:27448141-CAAA-41AE-8300-6EC65A1CD809,The mean percentage increase in the glipizide AUC after fluconazole administration was 56.9% (range: 35 to 81),ncit:positive,ncit:quantitative,glipizide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,fluconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:5E99691A-42F2-48FB-8AC7-057605A8DC5D,"Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine",ncit:positive,ncit:quantitative,mesoridazine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction,fluvoxamine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:7FCF9F18-AEB0-4D5C-9C3F-39A33A178996,"Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine",ncit:positive,ncit:quantitative,sulforidazine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction,fluvoxamine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:45B3901B-CFCD-4266-A3F0-792F7508582C,"Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine",ncit:positive,ncit:quantitative,thioridazine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,fluvoxamine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:2017F081-4F13-433A-B128-F008D39E2F43,"Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin",ncit:positive,ncit:Qualitative,sulfinpyrazone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,nitrofurantoin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:2C219739-5142-4F9A-8554-9AF1B6DB7732,"Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin. The resulting increase in nitrofurantoin serum levels may increase toxicity, and the decreased urinary levels could lessen its efficacy as a urinary tract antibacterial",ncit:positive,ncit:Qualitative,nitrofurantoin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,probenecid,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:E0F8C788-6072-405E-B77D-AFFCEC2584FD,"Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin",ncit:positive,ncit:Qualitative,nitrofurantoin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,probenecid,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:5A6C5A55-A20D-4125-8B49-C387042A6EA7,"Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin. The resulting increase in nitrofurantoin serum levels may increase toxicity, and the decreased urinary levels could lessen its efficacy as a urinary tract antibacterial",ncit:positive,ncit:Qualitative,sulfinpyrazone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,nitrofurantoin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:58E6585B-A4F0-4779-8AED-379333499F84,"Antacids containing magnesium trisilicate, when administered concomitantly with nitrofurantoin, reduce both the rate and extent of absorption",ncit:positive,ncit:Qualitative,magnesium trisilicate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,nitrofurantoin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:1AC7B4E6-95F6-4E6A-9024-1A1F205BDD01,There was no significant pharmacokinetic interaction between fluconazole and azithromycin,ncit:negative,ncit:quantitative,azithromycin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,fluconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:06AA0BDE-A517-4AD8-920C-501F63C5A32F,There was no significant pharmacokinetic interaction between fluconazole and azithromycin,ncit:negative,ncit:quantitative,azithromycin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,fluconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:EFDAB7AD-37F7-4A96-859E-7EF64F0A3A7C,"On the first day of dosing, fluconazole increased the midazolam AUC and Cmax by 259% and 150%, respectively",ncit:positive,ncit:quantitative,fluconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,midazolam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:9718E1B4-C9C0-4FE1-B59B-B7BB00CD66C8,"On the sixth day of dosing, fluconazole increased the midazolam AUC and Cmax by 259% and 74%, respectively",ncit:positive,ncit:quantitative,fluconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,midazolam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:8654C10C-E205-4971-A680-569491468541,Fluconazole reduced the clearance of IV midazolam by 51%,ncit:positive,ncit:quantitative,Fluconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,midazolam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:25E63A3A-8D98-4E47-A1C5-080E457E322A,The AUC and Cmax of glyburide (5 mg single dose) were significantly increased following the administration of fluconazole in 20 normal male volunteers,ncit:positive,ncit:Qualitative,glyburide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,fluconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:B39E6F00-268E-4077-8543-44ECEBD7B767,The AUC and Cmax of glyburide (5 mg single dose) were significantly increased following the administration of fluconazole in 20 normal male volunteers. There was a mean ± SD increase in AUC of 44% ± 29% (range: -13 to 115%) and Cmax increased 19% ± 19% (range: -23 to 62%),ncit:positive,ncit:quantitative,glyburide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,fluconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:9D550D24-9BFB-447E-9371-4C7DBEC5C2DB,The AUC and Cmax of glipizide (2.5 mg single dose) were significantly increased following the administration of fluconazole in 13 normal male volunteers,ncit:positive,ncit:Qualitative,fluconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,glipizide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:D78DC981-63C8-4A7D-8015-EE84697C89D3,The AUC and Cmax of glipizide (2.5 mg single dose) were significantly increased following the administration of fluconazole in 13 normal male volunteers. There was a mean ± SD increase in AUC of 49% ± 13% (range: 27 to 73%) and an increase in Cmax of 19% ± 23% (range: -11 to 79%).,ncit:positive,ncit:quantitative,fluconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,glipizide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:68DA4E3C-6DDE-4E8E-AD7D-461206A26D0C,"In 13 normal male volunteers, there was significant increase in tolbutamide (500 mg single dose) AUC and Cmax following the administration of fluconazole. There was a mean ± SD increase in tolbutamide AUC of 26% ± 9% (range: 12 to 39%). Tolbutamide Cmax increased 11% ± 9% (range: -6 to 27%).",ncit:positive,ncit:quantitative,fluconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,Tolbutamide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:70836966-FB70-4A37-991F-91F55317DD57,"The pharmacokinetics of theophylline were determined from a single intravenous dose of aminophylline (6 mg/kg) before and after the oral administration of fluconazole 200 mg daily for 14 days in 16 normal male volunteers. There were significant increases in theophylline AUC, Cmax, and half-life with a corresponding decrease in clearance. The mean ± SD theophylline AUC increased 21% ± 16% (range: -5 to 48%). The Cmax increased 13% ± 17% (range: -13 to 40%). Theophylline clearance decreased 16% ± 11 % (range: -32 to 5%). The half-life of theophylline increased from 6.6 ± 1.7 hours to 7.9 ± 1.5 hours.",ncit:positive,ncit:quantitative,fluconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,theophylline,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:BAC91CCB-1827-44C0-9226-6EF0E8DCE447,"There was a significant increase in cyclosporine AUC, Cmax, Cmin (24-hour concentration), and a significant reduction in apparent oral clearance following the administration of fluconazole. The mean ± SD increase in AUC was 92% ± 43% (range: 18 to 147%). The Cmax increased 60% ± 48% (range: -5 to 133%). The Cmin increased 157% ± 96% (range: 33 to 360%). The apparent oral clearance decreased 45% ± 15% (range: -15 to -60%)",ncit:positive,ncit:quantitative,fluconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,cyclosporine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:951CC546-3CF3-4CE5-942A-D5F1E731F5E8,"Phenytoin AUC was determined after 4 days of phenytoin dosing (200 mg daily, orally for 3 days followed by 250 mg intravenously for one dose) both with and without the administration of fluconazole (oral fluconazole 200 mg daily for 16 days) in 10 normal male volunteers. There was a significant increase in phenytoin AUC. The mean ± SD increase in phenytoin AUC was 88% ± 68% (range: 16 to 247%).",ncit:positive,ncit:quantitative,fluconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,Phenytoin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:894F9CAC-BDA9-408C-B662-4A896F86C06E,Administration of a single oral 200 mg dose of fluconazole after 15 days of rifampin administered as 600 mg daily in eight healthy male volunteers resulted in a significant decrease in fluconazole AUC and a significant increase in apparent oral clearance of fluconazole. There was a mean ± SD reduction in fluconazole AUC of 23% ± 9% (range: -13 to -42%). Apparent oral clearance of fluconazole increased 32% ± 17% (range: 16 to 72%). Fluconazole half-life decreased from 33.4 ± 4.4 hours to 26.8 ± 3.9 hours.,ncit:positive,ncit:Qualitative,rifampin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,fluconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:2695687D-25A2-4685-AF59-B4846213C148,"After the administration of cimetidine, there was a significant decrease in fluconazole AUC and Cmax. There was a mean ± SD decrease in fluconazole AUC of 13% ± 11% (range: -3.4 to -31%) and Cmax decreased 19% ± 14% (range: -5 to -40%). ",ncit:positive,ncit:Qualitative,fluconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,cimetidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:E48BE3FA-EC55-4D00-8348-7636211D0C86,"However, the administration of cimetidine 600 mg to 900 mg intravenously over a four-hour period (from one hour before to 3 hours after a single oral dose of fluconazole 200 mg) did not affect the bioavailability or pharmacokinetics of fluconazole in 24 healthy male volunteers.",ncit:negative,ncit:quantitative,fluconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,cimetidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:048EDB09-D902-45D5-9B23-BF0FFE3E5457,There was no significant difference in ethinyl estradiol or levonorgestrel AUC after the administration of 50 mg of fluconazole.,ncit:negative,ncit:Qualitative,fluconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,levonorgestrel,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:5AB5A1B5-99D4-4E0F-A408-1B470ADF4AAB,There was no significant difference in ethinyl estradiol or levonorgestrel AUC after the administration of 50 mg of fluconazole.,ncit:negative,ncit:Qualitative,ethinyl estradiol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,fluconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:67AEA12E-D072-42F8-8F51-6C3FDC2B3BE8,The individual AUC values of norethindrone decreased very slightly (<5%) in 3 of the 21 subjects after fluconazole treatment,ncit:positive,ncit:Qualitative,norethindrone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,fluconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:DAD30021-A51E-41B4-A144-876521E2D418,"In this placebo-controlled, double-blind, randomized, two-way crossover study carried out over three cycles of oral contraceptive treatment, fluconazole dosing resulted in small increases in the mean AUCs of ethinyl estradiol and norethindrone compared to similar placebo dosing.",ncit:positive,ncit:Qualitative,fluconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,ethinyl estradiol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:3EDA8231-21CC-4DCD-9976-3E5EFFBE5CD3,Fluconazole treatment did not cause a decrease in the ethinyl estradiol AUC of any individual subject in this study compared to placebo dosing,ncit:negative,ncit:Qualitative,ethinyl estradiol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Fluconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:44EC3110-B22E-41CB-B110-BA9C377348D0,"In this placebo-controlled, double-blind, randomized, two-way crossover study carried out over three cycles of oral contraceptive treatment, fluconazole dosing resulted in small increases in the mean AUCs of ethinyl estradiol and norethindrone compared to similar placebo dosing. The mean AUCs of ethinyl estradiol and norethindrone increased by 24% (95% C.I. range 18 to 31%) and 13% (95% C.I. range 8 to 18%), respectively relative to placebo.",ncit:positive,ncit:quantitative,ethinyl estradiol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,fluconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:EAB07FD4-0E93-419D-BA2B-D083F711E3EA,"In this placebo-controlled, double-blind, randomized, two-way crossover study carried out over three cycles of oral contraceptive treatment, fluconazole dosing resulted in small increases in the mean AUCs of ethinyl estradiol and norethindrone compared to similar placebo dosing. The mean AUCs of ethinyl estradiol and norethindrone increased by 24% (95% C.I. range 18 to 31%) and 13% (95% C.I. range 8 to 18%), respectively relative to placebo.",ncit:positive,ncit:quantitative,fluconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,norethindrone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:7091A47E-95D0-41C6-9886-8D81B84968C3,"In this placebo-controlled, double-blind, randomized, two-way crossover study carried out over three cycles of oral contraceptive treatment, fluconazole dosing resulted in small increases in the mean AUCs of ethinyl estradiol and norethindrone compared to similar placebo dosing.",ncit:positive,ncit:Qualitative,fluconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,norethindrone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:972ADF5B-CAC7-4582-B418-89E8DECF8DF9,"In a crossover clinical study, 72 healthy subjects were administered Plavix (300 mg loading dose followed by 75 mg per day) alone and with omeprazole (80 mg at the same time as Plavix) for 5 days. The exposure to the active metabolite of clopidogrel was decreased by 46% (Day 1) and 42% (Day 5) when Plavix and omeprazole were administered together",ncit:positive,ncit:quantitative,omeprazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,Plavix,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:0136CC87-315F-41FE-BE0C-D5FF135D8C86,"Although the administration of clopidogrel 75 mg per day did not modify the pharmacokinetics of S-warfarin (a CYP2C9 substrate) or INR in patients receiving long-term warfarin therapy, coadministration of Plavix with warfarin increases the risk of bleeding because of independent effects on hemostasis",ncit:negative,ncit:quantitative,clopidogrel,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,warfarin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:5a25e425-ac1b-41db-ac92-9e5cb0f2f464,Desipramine Blood levels of desipramine have increased with concurrent methadone administration.,ncit:positive,ncit:Qualitative,desipramine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,methadone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:dfdccc3f-acc8-44bd-9f1a-32ccfe94ed96,"Voriconazole Repeat dose administration of oral voriconazole (400mg Q12h for 1 day, then 200mg Q12h for 4 days) increased the Cmax and AUC of (R)-methadone by 31% and 47%, respectively, in subjects receiving a methadone maintenance dose (30 to 100 mg QD). ",ncit:positive,ncit:quantitative,methadone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,voriconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:17723BC7-2A48-4A6B-8840-B91B644C285F,"In a pharmacokinetic study with patients on methadone maintenance therapy, phenytoin administration (250 mg b.i.d. initially for 1 day followed by 300 mg QD for 3 to 4 days) resulted in an approximately 50% reduction in methadone exposure and withdrawal symptoms occurred concurrently",ncit:positive,ncit:quantitative,methadone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,phenytoin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:52665C3E-A2F1-4246-B527-F133C049F3F2,"In patients well-stabilized on methadone, concomitant administration of rifampin resulted in a marked reduction in serum methadone levels and a concurrent appearance of withdrawal symptom",ncit:positive,ncit:Qualitative,methadone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,rifampin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:D18B3128-337B-47F7-A303-89BE7F55FD21,Experimental evidence demonstrated that methadone increased the area under the concentration-time curve (AUC) of zidovudine which could result in toxic effects,ncit:positive,ncit:Qualitative,zidovudine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,methadone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:BB0CD39B-55EA-407A-B805-E86EC43F0B11,"Experimental evidence demonstrated that methadone decreased the AUC and peak levels for didanosine and stavudine, with a more significant decrease for didanosine. Methadone disposition was not substantially altered",ncit:negative,ncit:Qualitative,methadone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,stavudine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:26AFAB04-8ACB-4637-AB87-C5EC22A3A6CE,"Experimental evidence demonstrated that methadone decreased the AUC and peak levels for didanosine and stavudine, with a more significant decrease for didanosine. Methadone disposition was not substantially altered",ncit:negative,ncit:Qualitative,methadone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,didanosine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:7D3B1848-2B70-465B-BE4B-9CC69BCF25BF,"Experimental evidence demonstrated that methadone decreased the AUC and peak levels for didanosine and stavudine, with a more significant decrease for didanosine",ncit:positive,ncit:Qualitative,methadone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,stavudine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:131C0FDC-AA2B-46C9-903C-D995D276211B,"Experimental evidence demonstrated that methadone decreased the AUC and peak levels for didanosine and stavudine, with a more significant decrease for didanosine",ncit:positive,ncit:Qualitative,didanosine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,methadone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:38964317-E23D-4943-8C5F-0968BD075EAC,"However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected patients",ncit:negative,ncit:quantitative,lamivudine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,ribavirin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:261AE364-EFBE-4C3B-8086-4DDDCA2E587E,"However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected patients",ncit:negative,ncit:quantitative,ribavirin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,stavudine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:D6A29949-A24F-4F49-A9E5-094DAF42F80C,"Although data are limited, methadone maintenance therapy in 5 pregnant women did not appear to alter zidovudine pharmacokinetics",ncit:negative,ncit:Qualitative,zidovudine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,methadone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:E5106C65-D5C3-41C1-8E40-AACF6550C865,"However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected patients ",ncit:negative,ncit:quantitative,ribavirin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,zidovudine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:C0B798A3-2EAA-4345-BC1D-5FABA5F59E3F,"However, in a pharmacokinetic interaction study in which 12 HIV-1-positive volunteers received a single 300 mg phenytoin dose alone and during steady-state zidovudine conditions (200 mg every 4 hours), no change in phenytoin kinetics was observed. Although not designed to optimally assess the effect of phenytoin on zidovudine kinetics, a 30% decrease in oral zidovudine clearance was observed with phenytoin",ncit:positive,ncit:quantitative,phenytoin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,zidovudine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:4E2648E5-AA9C-4000-BB52-879FFEF1E4A0,"However, in a pharmacokinetic interaction study in which 12 HIV-1-positive volunteers received a single 300 mg phenytoin dose alone and during steady-state zidovudine conditions (200 mg every 4 hours), no change in phenytoin kinetics was observed",ncit:negative,ncit:quantitative,phenytoin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,zidovudine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:C30A4D57-8DEC-4CFA-ADE5-6452A74E2BA0,"Phenytoin plasma levels have been reported to be low in some patients receiving zidovudine, while in one case a high level was documented",ncit:positive,ncit:Qualitative,Phenytoin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,zidovudine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:854664F0-76E7-4565-BB4A-8507AAF8A694,"At low doses the differences are greater, with slow metabolizers attaining concentrations about 3 to 4 times higher than extensive metabolizers. In extensive metabolizers, saturation of the hydroxylation pathway (CYP2D6) results in greater-than-linear increases in plasma levels following administration of RYTHMOL SR capsules. In slow metabolizers, propafenone pharmacokinetics is linear. Because the difference decreases at high doses and is mitigated by the lack of the active 5-hydroxymetabolite in the slow metabolizers, and because steady-state conditions are achieved after 4 to 5 days of dosing in all patients, the recommended dosing regimen of RYTHMOL SR is the same for all patients. The larger inter-subject variability in blood levels require that the dose of the drug be titrated carefully in patients with close attention paid to clinical and ECG evidence of toxicity",ncit:positive,ncit:Qualitative,propafenone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,RYTHMOL SR capsules,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:D70FFDA0-120E-428E-9A14-7428583DC2F0,"Drugs that inhibit CYP2D6 (such as desipramine, paroxetine, ritonavir, sertraline) and CYP3A4 (such as ketoconazole, ritonavir, saquinavir, erythromycin, and grapefruit juice) can be expected to cause increased plasma levels of propafenone",ncit:positive,ncit:Qualitative,desipramine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,propafenone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:70B5F31C-1AC5-4503-9595-2482BD7B2095,"Drugs that inhibit CYP2D6 (such as desipramine, paroxetine, ritonavir, sertraline) and CYP3A4 (such as ketoconazole, ritonavir, saquinavir, erythromycin, and grapefruit juice) can be expected to cause increased plasma levels of propafenone",ncit:positive,ncit:Qualitative,propafenone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,ritonavir,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:07B4691D-3234-4A1D-B636-38E22FE32363,Concomitant administration of rifampin and propafenone in extensive metabolizers decreased the plasma concentrations of propafenone by 67% with a corresponding decrease of 5OH-propafenone by 65%,ncit:positive,ncit:quantitative,propafenone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,rifampin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:1F05CBB2-3F06-46A5-9AED-2BF36ABD271C,Concomitant administration of propafenone immediate release tablets and cimetidine in 12 healthy subjects resulted in a 20% increase in steady-state plasma concentrations of propafenone,ncit:positive,ncit:quantitative,propafenone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,cimetidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:922E8111-2752-46F9-9FB0-075DDBE68627,No significant effects on the pharmacokinetics of propafenone or lidocaine have been seen following their concomitant use in patients,ncit:negative,ncit:quantitative,propafenone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,lidocaine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:9A39BBF7-3F9E-475D-8205-F910387028B4,"Drugs that inhibit CYP2D6 (such as desipramine, paroxetine, ritonavir, sertraline) and CYP3A4 (such as ketoconazole, ritonavir, saquinavir, erythromycin, and grapefruit juice) can be expected to cause increased plasma levels of propafenone",ncit:positive,ncit:Qualitative,propafenone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,sertraline,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:D9BC84FF-EFC4-45AB-BAC6-5E24D017F4F3,The pharmacokinetics of propafenone was not affected by the coadministration of either propranolol or metoprolol,ncit:negative,ncit:quantitative,propafenone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,metoprolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:8BC14C68-A16B-478F-A271-3F5339335684,"Drugs that inhibit CYP2D6 (such as desipramine, paroxetine, ritonavir, sertraline) and CYP3A4 (such as ketoconazole, ritonavir, saquinavir, erythromycin, and grapefruit juice) can be expected to cause increased plasma levels of propafenone",ncit:positive,ncit:Qualitative,erythromycin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,propafenone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:36E57B99-7326-406B-9645-56C2E6F9579F,"Drugs that inhibit CYP2D6 (such as desipramine, paroxetine, ritonavir, sertraline) and CYP3A4 (such as ketoconazole, ritonavir, saquinavir, erythromycin, and grapefruit juice) can be expected to cause increased plasma levels of propafenone",ncit:positive,ncit:Qualitative,propafenone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,paroxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:7FCFECD6-5FF3-4E23-9209-9C7E8F479C9C,"Drugs that inhibit CYP2D6 (such as desipramine, paroxetine, ritonavir, sertraline) and CYP3A4 (such as ketoconazole, ritonavir, saquinavir, erythromycin, and grapefruit juice) can be expected to cause increased plasma levels of propafenone",ncit:positive,ncit:Qualitative,saquinavir,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,propafenone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:EDFC11A6-B002-4B15-9DBF-7F5E1C0013B2,"In 4 patients, administration of metoprolol with propafenone increased the metoprolol plasma concentrations at steady state by 100-400%",ncit:positive,ncit:quantitative,metoprolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,propafenone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:8BFA4DB1-60D1-4205-B590-FA184A489FED,Concomitant use of propafenone and propranolol in healthy subjects increased propranolol plasma concentrations at steady state by 113%,ncit:positive,ncit:quantitative,propranolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,propafenone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:3B8F388D-66EB-4C4C-A08C-19897EB840C2,Concomitant administration of propafenone and fluoxetine in extensive metabolizers increased the S propafenone Cmax and AUC by 39 and 50% and the R propafenone Cmax and AUC by 71 and 50%,ncit:positive,ncit:quantitative,fluoxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,propafenone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:4FD6C3F9-C130-4F82-9422-69A1374F9CF1,No significant effects on the pharmacokinetics of propafenone or lidocaine have been seen following their concomitant use in patients,ncit:negative,ncit:quantitative,propafenone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,lidocaine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:A73F4920-B347-4A28-9734-E43F043CEC39,"Drugs that inhibit CYP2D6 (such as desipramine, paroxetine, ritonavir, sertraline) and CYP3A4 (such as ketoconazole, ritonavir, saquinavir, erythromycin, and grapefruit juice) can be expected to cause increased plasma levels of propafenone",ncit:positive,ncit:Qualitative,ritonavir,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,propafenone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:F5F8B3B5-DD6D-4768-8330-8F4AEF805412,"Drugs that inhibit CYP2D6 (such as desipramine, paroxetine, ritonavir, sertraline) and CYP3A4 (such as ketoconazole, ritonavir, saquinavir, erythromycin, and grapefruit juice) can be expected to cause increased plasma levels of propafenone",ncit:positive,ncit:Qualitative,ketoconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,propafenone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:4327A41F-32B3-4F08-B6FF-F249F4F40D92,Concomitant administration of rifampin and propafenone in extensive metabolizers decreased the plasma concentrations of propafenone by 67% with a corresponding decrease of 5OH-propafenone by 65%,ncit:positive,ncit:quantitative,rifampin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,5OH-propafenone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:922F83C3-5299-4165-8FC7-847BC2E776DB,A 100 mg dose of quinidine increased steady state concentrations of propafenone 3-fold,ncit:positive,ncit:quantitative,quinidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,propafenone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:A3A3C4C7-9B41-4BDF-9967-F46B73678A9C,The pharmacokinetics of propafenone was not affected by the coadministration of either propranolol or metoprolol,ncit:negative,ncit:quantitative,propranolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,propafenone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:EFFB1FEA-EFFD-4675-A2C1-EF7FF4C3B113,"Concomitant administration of quinidine (50 mg three times daily) with 150 mg immediate-release propafenone three times daily decreased the clearance of propafenone by 60% in EM, making them PM. Steady-state plasma concentrations increased by more that 2-fold for propafenone, and decreased 50% for 5OH-propafenone.",ncit:positive,ncit:quantitative,quinidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,propafenone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:E3F119C9-373F-4543-BCA1-D1EA80B6213A,The concomitant administration of propafenone and warfarin increased warfarin plasma concentrations at steady state by 39% in healthy volunteers and prolonged the prothrombin time (PT) in patients taking warfarin. ,ncit:positive,ncit:quantitative,warfarin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,propafenone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:DAA66020-106E-48D8-B6BE-0005C2E7EEEE,"Concomitant administration of rifampin and propafenone in extensive metabolizers decreased the plasma concentrations of propafenone by 67% with a corresponding decrease of 5OH-propafenone by 65%. The concentrations of norpropafenone increased by 30%. In poor metabolizers, there was a 50% decrease in propafenone plasma concentrations and increased the AUC and Cmax of norpropafenone by 74 and 20%, respectively. Urinary excretion of propafenone and its metabolites decreased significantly. Similar results were noted in elderly patients: Both the AUC and Cmax propafenone decreased by 84%, with a corresponding decrease in AUC and Cmax of 5OH-propafenone by 69 and 57%",ncit:positive,ncit:quantitative,5OH-propafenone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction,rifampin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:37F0D015-2408-4E0C-8DB7-70A4176385EA,"Concomitant administration of rifampin and propafenone in extensive metabolizers decreased the plasma concentrations of propafenone by 67% with a corresponding decrease of 5OH-propafenone by 65%. The concentrations of norpropafenone increased by 30%. In poor metabolizers, there was a 50% decrease in propafenone plasma concentrations and increased the AUC and Cmax of norpropafenone by 74 and 20%, respectively",ncit:positive,ncit:quantitative,propafenone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,rifampin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:0E5312E9-937E-4506-BF67-64387D9AB7C9,"Concomitant use of propafenone and digoxin increased steady-state serum digoxin exposure (AUC) in patients by 60 to 270%, and decreased the clearance of digoxin by 31 to 67%",ncit:positive,ncit:quantitative,propafenone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,digoxin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:F6E73E07-3048-4238-A362-91A5247AF411,"Concomitant administration of quinidine (50 mg three times daily) with 150 mg immediate-release propafenone three times daily decreased the clearance of propafenone by 60% in EM, making them PM. Steady-state plasma concentrations increased by more that 2-fold for propafenone, and decreased 50% for 5OH-propafenone",ncit:positive,ncit:quantitative,5OH-propafenone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction,quinidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:B75C1934-6E6E-4E1F-A355-FD3F9C78AC2A,"Concomitant administration of rifampin and propafenone in extensive metabolizers decreased the plasma concentrations of propafenone by 67% with a corresponding decrease of 5OH-propafenone by 65%. The concentrations of norpropafenone increased by 30%. In poor metabolizers, there was a 50% decrease in propafenone plasma concentrations and increased the AUC and Cmax of norpropafenone by 74 and 20%, respectively. Urinary excretion of propafenone and its metabolites decreased significantly. Similar results were noted in elderly patients: Both the AUC and Cmax propafenone decreased by 84%, with a corresponding decrease in AUC and Cmax of 5OH-propafenone by 69 and 57%",ncit:positive,ncit:quantitative,rifampin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,propafenone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:B78D3AA4-4026-48DC-82D7-6DF683CBA40F,"Concomitant administration of rifampin and propafenone in extensive metabolizers decreased the plasma concentrations of propafenone by 67% with a corresponding decrease of 5OH-propafenone by 65%. The concentrations of norpropafenone increased by 30%. In poor metabolizers, there was a 50% decrease in propafenone plasma concentrations and increased the AUC and Cmax of norpropafenone by 74 and 20%, respectively. Urinary excretion of propafenone and its metabolites decreased significantly. ",ncit:positive,ncit:Qualitative,metabolites,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction,rifampin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:615C0715-009A-434C-B361-D8025F1C0A19,Concomitant administration of rifampin and propafenone in extensive metabolizers decreased the plasma concentrations of propafenone by 67% with a corresponding decrease of 5OH-propafenone by 65%. The concentrations of norpropafenone increased by 30%,ncit:positive,ncit:quantitative,norpropafenone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction,rifampin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:EAF5ABD0-B974-4DCB-9DC2-21DEBA007B73,"Concomitant administration of quinidine (50 mg three times daily) with 150 mg immediate-release propafenone three times daily decreased the clearance of propafenone by 60% in EM, making them PM",ncit:positive,ncit:quantitative,quinidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,immediate-release propafenone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:3B24C819-CE68-4748-97F7-68F2A9F0B89E,Concomitant administration of fluvastatin (40 mg) and itraconazole (100 mg daily x 4 days) does not affect plasma itraconazole or fluvastatin levels,ncit:negative,ncit:quantitative,fluvastatin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,itraconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:7EF94081-F961-4EC3-BFFC-9BCF936E9081,Concomitant administration of fluvastatin (40 mg) and itraconazole (100 mg daily x 4 days) does not affect plasma itraconazole or fluvastatin levels,ncit:negative,ncit:quantitative,fluvastatin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,itraconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:4CC99096-3D63-42D4-973E-076D0C4DF9D5,"In a placebo-controlled trial in normal volunteers, administration of sertraline for 17 days (including 200 mg/day for the last 10 days) did not change serum digoxin levels or digoxin renal clearance",ncit:negative,ncit:quantitative,sertraline,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,digoxin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:363220D6-B325-499D-A95B-3372D7AE439C,"In a pharmacokinetic study between atazanavir 400 mg once daily and diltiazem 180 mg once daily, a CYP3A substrate, there was a 2-fold increase in the diltiazem plasma concentration and an additive effect on the PR interval.",ncit:positive,ncit:quantitative,atazanavir,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,diltiazem,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:DC53D35A-E5B2-4251-8CD1-F97A95820653,"In a pharmacokinetic study between atazanavir 400 mg once daily and atenolol 50 mg once daily, there was no substantial additive effect of atazanavir and atenolol on the PR interval. [",ncit:negative,ncit:quantitative,atazanavir,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,atenolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:ec45f2d6-22be-4c2e-8738-6d8fadff5443,"Although the mechanism is not fully understood, cyclosporine has been shown to increase the AUC of statins. The increase in AUC for simvastatin acid is presumably due, in part, to inhibition of CYP3A4. ",ncit:positive,ncit:Qualitative,simvastatin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,cyclosporine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:3DF53145-533C-4042-BE99-5192CC9E8E91,Coadministration of simvastatin (40 mg QD for 10 days) resulted in an increase in the maximum mean levels of cardioactive digoxin (given as a single 0.4 mg dose on day 10) by approximately 0.3 ng/mL,ncit:positive,ncit:quantitative,digoxin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,simvastatin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:03848CDE-BE3A-45B3-A6DD-4B788F8133B8,"In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin. ",ncit:negative,ncit:quantitative,erythromycin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,simvastatin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:368E6ECC-82BE-4305-B5DE-BB049E896446,"In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin. ",ncit:negative,ncit:quantitative,midazolam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,simvastatin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:AA651EA9-6A07-44C3-A582-07710CB78A80,"In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.",ncit:positive,ncit:Qualitative,simvastatin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,digoxin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:FBEF1F68-38A0-4109-A395-B7F1BFA258AF,"In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and lansoprazole delayed-release capsules 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate.",ncit:negative,ncit:quantitative,naproxen,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,7-hydroxymethotrexate.,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:76C97797-1CC2-4D65-B802-A1C3636C1A06," In a single-dose crossover study examining lansoprazole delayed-release capsules 30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate.",ncit:positive,ncit:quantitative,lansoprazole delayed-release capsules,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:object-drug-of-interaction,sucralfate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:94B24F1D-6A9E-4A61-841A-7B34A381FA39,"It is theoretically possible that lansoprazole may interfere with the absorption of other drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, ampicillin esters, iron salts, digoxin)",ncit:positive,ncit:Qualitative,ampicillin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,lansoprazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:162F1620-4242-4BEF-B6CF-5968B754C196,"In a single-dose crossover study examining lansoprazole delayed-release capsules 30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate. ",ncit:positive,ncit:quantitative,sucralfate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,omeprazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:72FEC38A-882B-46DB-957F-06691CA3C4AE,"It is theoretically possible that lansoprazole may interfere with the absorption of other drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, ampicillin esters, iron salts, digoxin).",ncit:positive,ncit:Qualitative,lansoprazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,digoxin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:29FD1F33-9E15-44C9-A823-61CC96ADD643,"It is theoretically possible that lansoprazole may interfere with the absorption of other drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, ampicillin esters, iron salts, digoxin)",ncit:positive,ncit:Qualitative,lansoprazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,ketoconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:0C12654D-F1AA-4FAE-8843-FBFF8814AC25,"lansoprazole delayed-release capsules substantially decreases the systemic concentrations of the HIV protease inhibitor atazanavir, ",ncit:positive,ncit:Qualitative,atazanavir,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,lansoprazole delayed-release capsules,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:3CBDCB01-3563-48D7-8EFB-22C1636BAE67,"In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and lansoprazole delayed-release capsules 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate.",ncit:negative,ncit:quantitative,lansoprazole delayed-release capsules,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,7-hydroxymethotrexate.,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:5E0AF4F7-EC19-4CBD-93BE-E54215621396,"It is theoretically possible that lansoprazole may interfere with the absorption of other drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, ampicillin esters, iron salts, digoxin)",ncit:positive,ncit:Qualitative,iron,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,lansoprazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:DC004676-53CA-4434-A3DA-20C91D4166A7,"When lansoprazole delayed-release capsules were administered concomitantly with theophylline (CYP1A2, CYP3A), a minor increase (10%) in the clearance of theophylline was seen. ",ncit:positive,ncit:quantitative,lansoprazole delayed-release capsules,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,theophylline,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:FAF17A85-465C-4DBC-85FE-A48DEADD92B4,"In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and lansoprazole delayed-release capsules 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate",ncit:negative,ncit:quantitative,methotrexate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,naproxen,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:B1D0B118-EA53-4571-AFA4-8281B0252E9B,"In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and lansoprazole delayed-release capsules 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate.",ncit:negative,ncit:quantitative,methotrexate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,lansoprazole delayed-release capsules,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:04EF641A-1135-45A8-A2A5-3162B0AB2E8A,"In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin ",ncit:negative,ncit:quantitative,warfarin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,lansoprazole delayed-release capsules,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:46E913B1-45BC-45CC-B734-9C965FB8E765,"It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole)",ncit:positive,ncit:Qualitative,lansoprazole delayed-release capsules,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,iron,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:16C079FF-E147-4762-98D5-72B22120266A,"It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole)",ncit:positive,ncit:Qualitative,lansoprazole delayed-release capsules,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,ketoconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:C27DD369-37E4-42E5-9F1C-763C9717960D,A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline,ncit:positive,ncit:quantitative,theophylline,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,lansoprazole delayed-release capsules,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:2DA81FAC-5FAF-4CB5-9A21-A2B6853779B8,"It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole)",ncit:positive,ncit:Qualitative,ampicillin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,lansoprazole delayed-release capsules,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:A32087FE-862A-42FB-BFB6-E92368DFAD7E,Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus,ncit:positive,ncit:Qualitative,lansoprazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,tacrolimus,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:579CFDC0-7C0E-4858-83FB-607D2FCB5402,"Lansoprazole delayed-release capsules and other PPIs are likely to substantially decrease the systemic concentrations of the HIV protease inhibitor atazanavir,",ncit:positive,ncit:Qualitative,Lansoprazole delayed-release capsules,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,atazanavir,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:80D94EDA-BB59-4999-ACF1-6CA41C9E5C0E,"It is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole)",ncit:positive,ncit:Qualitative,digoxin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,lansoprazole delayed-release capsules,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:D110C3E4-83B1-41E3-88DA-3F23331919FE,Increased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels,ncit:positive,ncit:Qualitative,verapamil,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,lithium,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:36F06302-DF36-4A6D-BF27-AF69DD7B86B9,A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil,ncit:positive,ncit:Qualitative,metoprolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,verapamil,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:ff495abf-5f25-4f26-adee-58b9054fba22,"Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity. In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified. Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively. ",ncit:positive,ncit:quantitative,digoxin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,verapamil,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:1f9e2a7d-2168-48c6-b85e-76da734bbbb3,7.19 Phenobarbital Phenobarbital therapy may increase verapamil clearance. 7.20 Rifampin Therapy with rifampin may markedly reduce oral verapamil bioavailability. 7.21 Theophylline Verapamil may inhibit the clearance and increase the plasma levels of theophylline. ,ncit:positive,ncit:Qualitative,Phenobarbital,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,verapamil,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:3BE6E8E3-9140-410B-9949-8151B2438BEB,ncreased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels,ncit:negative,ncit:Qualitative,lithium,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,verapamil,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:c6f43390-ae76-4690-ae7a-40db34e5c3c9,"The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens. Concomitant administration of R-verapamil can decrease the clearance of paclitaxel. ",ncit:positive,ncit:Qualitative,prednisone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,verapamil,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:C4A8B913-B9DF-4F55-A1DE-A32BD695EB11,Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol,ncit:positive,ncit:Qualitative,Verapamil,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,ethanol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:E4505292-6DCC-4A68-A62B-E25961ECF68D,Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.,ncit:positive,ncit:Qualitative,verapamil,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,paclitaxel,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:858D9DA0-485E-4555-B054-651B701C5036,"Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g., erythromycin, ritonavir) causing elevation of plasma levels of verapamil",ncit:positive,ncit:Qualitative,verapamil,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,ritonavir,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:F35EB2D1-9690-4A4E-B23E-182819B3ED1D,"However, the addition of verapamil has also resulted in the lowering of serum lithium levels in patients receiving chronic stable oral lithium",ncit:positive,ncit:Qualitative,lithium,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,verapamil,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:27707E0B-1375-45BB-A2A3-98F020450726,"Inducers of CYP3A4 (e.g., rifampin) have caused a lowering of plasma levels of verapamil.",ncit:positive,ncit:Qualitative,rifampin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,verapamil,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:fa818c9e-2294-42d3-94d2-3ae3709e6b10,"The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens. Concomitant administration of R-verapamil can decrease the clearance of paclitaxel. ",ncit:positive,ncit:Qualitative,cyclophosphamide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,verapamil,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:447F6F2B-A317-477E-B4EA-0F97525C1311,Verapamil therapy may increase carbamazepine concentrations during combined therapy,ncit:positive,ncit:Qualitative,Verapamil,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,carbamazepine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:c49517bf-f512-4107-9f9b-2c8cf653d73e,7.20 Rifampin Therapy with rifampin may markedly reduce oral verapamil bioavailability. 7.21 Theophylline Verapamil may inhibit the clearance and increase the plasma levels of theophylline. ,ncit:positive,ncit:Qualitative,verapamil,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,rifampin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:7c177e71-023f-4b5c-aaa0-4198f3d75fa2,7.21 Theophylline Verapamil may inhibit the clearance and increase the plasma levels of theophylline. ,ncit:positive,ncit:Qualitative,Verapamil,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,theophylline,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:50A2A23D-5867-4325-B1B9-B97E8A6BA026,"The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.",ncit:positive,ncit:Qualitative,verapamil,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,adriamycin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:BCBB46BF-0BBB-447A-95EF-AFB163C9EDA0,"Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g., erythromycin, ritonavir) causing elevation of plasma levels of verapamil",ncit:positive,ncit:Qualitative,erythromycin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,verapamil,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:28D2FC94-324E-43D4-A267-C4212943EA77,The interaction between cimetidine and chronically administered verapamil has not been studied. Variable results on clearance have been obtained in acute studies of healthy volunteers; clearance of verapamil was either reduced or unchanged,ncit:positive,ncit:Qualitative,verapamil,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,cimetidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:5074B31D-685B-4729-801C-81569E9B7755,"The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens. ",ncit:positive,ncit:Qualitative,vindesine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,verapamil,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:CAC5A465-86D0-4410-97A7-ECCC4A00AD63,Verapamil therapy may increase serum levels of cyclosporine,ncit:positive,ncit:Qualitative,cyclosporine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Verapamil,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:E42A245B-CC65-4D92-B518-EA35FBE5072F,"The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.",ncit:positive,ncit:Qualitative,cisplatin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,verapamil,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:85ad02c7-6689-49ad-9fa4-8efe359ddae8,"The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens. Concomitant administration of R-verapamil can decrease the clearance of paclitaxel. ",ncit:positive,ncit:Qualitative,verapamil,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,procarbazine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:67f93bbe-d3fb-4a07-80a5-f1d251cfee91,"The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens. Concomitant administration of R-verapamil can decrease the clearance of paclitaxel. ",ncit:positive,ncit:Qualitative,verapamil,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,oncovin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:FDF3FFAB-CB56-4755-A459-4D6702D50F20,A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil,ncit:positive,ncit:Qualitative,verapamil,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,propranolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:A921A84D-2B3C-473E-8069-099D08E297DA,"Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively. ",ncit:positive,ncit:Qualitative,digitoxin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Verapamil,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:9bd1f5ec-5099-45d4-bb71-4ba333372d05,"7.8 Antineoplastic Agents Verapamil can increase doxorubicin levels. The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens. Concomitant administration of R-verapamil can decrease the clearance of paclitaxel. ",ncit:positive,ncit:Qualitative,doxorubicin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Verapamil,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:1E0066F3-88FA-4D21-AD45-F18E6B1D63AC,The interaction between cimetidine and chronically administered verapamil has not been studied. Variable results on clearance have been obtained in acute studies of healthy volunteers; clearance of verapamil was either reduced or unchanged,ncit:negative,ncit:Qualitative,cimetidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,verapamil,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:02343aa7-9637-46b4-a55f-c0d6639ed2e4,"Based on a clinical study of 5 liver transplant recipients, coadministration of tacrolimus with nelfinavir increased blood concentrations of tacrolimus significantly and, as a result, a reduction in the tacrolimus dose by an average of 16-fold was needed to maintain mean trough tacrolimus blood concentrations of 9.7 ng/mL. Thus, frequent monitoring of tacrolimus blood concentrations and appropriate dosage adjustments are essential when nelfinavir is used concomitantly. Tacrolimus may affect the pharmacokinetics of other drugs (e.g., phenytoin) and increase their concentration. ",ncit:positive,ncit:quantitative,nelfinavir,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,tacrolimus,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:2AE4C3BA-8FA0-4265-ACBC-F022AB946E76,"In addition, there was a significant increase in tacrolimus clearance (0.036±0.008 L/hr/kg vs. 0.053±0.010 L/hr/kg) with concomitant rifampin administration",ncit:positive,ncit:quantitative,tacrolimus,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,rifampin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:5C9B51D6-62BE-4AC8-B24A-9002CE96347E,The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide,ncit:negative,ncit:quantitative,irbesartan,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,nifedipine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:E5CDD635-1DEF-4A46-B34C-66CC6173CD05,Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics,ncit:negative,ncit:quantitative,hydrochlorothiazide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,irbesartan,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:A91585DB-6567-4C82-9FBD-5DC5DB1D639F,The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide,ncit:negative,ncit:quantitative,hydrochlorothiazide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,irbesartan,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:CF54466A-D6FE-450F-ABF1-2B738811B223,Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics,ncit:negative,ncit:quantitative,nifedipine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,irbesartan,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:018FEEC3-6E62-4194-8D18-3CB28BD77561,"However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible",ncit:negative,ncit:Qualitative,warfarin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,irbesartan,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:3D7FD74A-7F11-4208-9E07-2584F30F4723,"In a placebo-controlled trial in normal volunteers, administration of sertraline for 22 days (including 200 mg/day for the final 13 days) caused a statistically significant 16% decrease from baseline in the clearance of tolbutamide following an intravenous 1000 mg dose",ncit:positive,ncit:quantitative,tolbutamide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,sertraline,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:7421D0B5-DA5A-4227-9C25-2DB4A709F52D,"Sertraline administration did not noticeably change either the plasma protein binding or the apparent volume of distribution of tolbutamide, suggesting that the decreased clearance was due to a change in the metabolism of the drug",ncit:negative,ncit:quantitative,Sertraline,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,tolbutamide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:B2B024B5-A8FD-4AD7-8A85-560144BB2A77,"Clonazepam does not appear to alter the pharmacokinetics of phenytoin, carbamazepine or phenobarbital",ncit:negative,ncit:Qualitative,phenytoin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Clonazepam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:4C90E6DF-DF70-445D-A363-A3EE82D7423D,"Clonazepam does not appear to alter the pharmacokinetics of phenytoin, carbamazepine or phenobarbital",ncit:negative,ncit:Qualitative,Clonazepam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,carbamazepine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:0FA1BD38-A158-4BB4-B03D-3E9C742740D4,"Clonazepam does not appear to alter the pharmacokinetics of phenytoin, carbamazepine or phenobarbital",ncit:negative,ncit:Qualitative,phenobarbital,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Clonazepam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:E99F2872-08D6-4EA4-BD92-D6A23BF86BC8,"Cimetidine reduced the clearance and volume of distribution of meperidine and also the formation of the metabolite, normeperidine, in healthy subjects and thus, caution should be used with concomitant administration",ncit:positive,ncit:Qualitative,Cimetidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,meperidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:2E8FEFC1-11DB-475C-BB8D-F9566618953A,"Cimetidine reduced the clearance and volume of distribution of meperidine and also the formation of the metabolite, normeperidine, in healthy subjects and thus, caution should be used with concomitant administration",ncit:positive,ncit:Qualitative,Cimetidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,normeperidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:8958D91B-1B57-4DF5-9AD5-AF4CF63C817D,"Plasma concentrations of meperidine and its metabolite, normeperidine, may be increased by acyclovir, thus caution should be used with concomitant administration",ncit:positive,ncit:Qualitative,acyclovir,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,normeperidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:8EE6B83E-6A99-4F46-84BD-6628F6FBC13B,"Plasma concentrations of meperidine and its metabolite, normeperidine, may be increased by acyclovir, thus caution should be used with concomitant administration",ncit:positive,ncit:Qualitative,acyclovir,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,meperidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:51D8214B-B0EA-4A9B-8208-5127AF40F143,Coadministration of nelfinavir at steady-state with a single oral dose of azithromycin resulted in increased azithromycin serum concentrations,ncit:positive,ncit:Qualitative,nelfinavir,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,azithromycin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:7C7E6247-642A-4818-A72F-4C911D7D6679,"The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.",ncit:negative,ncit:quantitative,cisapride,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,sertraline,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:75D67E5F-83EE-4595-8A1D-9BD84FA753BF,"The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.",ncit:negative,ncit:quantitative,sertraline,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,terfenadine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:03C50FE5-5C88-4AEE-BA79-1A55F3ECC42D,"The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride",ncit:negative,ncit:quantitative,sertraline,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,carbamazepine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:9E10EDC8-FFEC-4F33-BBA4-5D39DCA6741F,Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).,ncit:positive,ncit:quantitative,sertraline,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,cisapride,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:78189578-F1FD-4387-9B97-F35445D29323,"Mexiletine does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to mexiletine hydrochloride USP capsules, has been reported to lower serum digoxin levels",ncit:negative,ncit:quantitative,digoxin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Mexiletine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:71C93955-5B49-4085-B96C-95AB3FEAD96E,"Mexiletine does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to mexiletine hydrochloride USP capsules, has been reported to lower serum digoxin levels",ncit:positive,ncit:Qualitative,digoxin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,magnesium-aluminum hydroxide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:F0C7E6A2-E1B7-48B3-B953-F7970BF88595,"In a formal, single-dose interaction study (n = 6 males) the clearance of mexiletine was decreased by 38% following the coadministration of fluvoxamine, an inhibitor of CYP1A2",ncit:positive,ncit:quantitative,mexiletine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,fluvoxamine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:AA39BECF-217C-458A-9F29-AFF8BD4E49A8,"In this crossover steady state study, the pharmacokinetics of propafenone were unaffected in either phenotype by the coadministration of mexiletine",ncit:negative,ncit:quantitative,propafenone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,mexiletine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:B1D9F1B0-501C-4E01-A67C-43B1CDA20EF5,"In another formal study (n = 8 extensive and n = 7 poor metabolizers of CYP2D6), coadministration of propafenone did not alter the kinetics of mexiletine in the poor CYP2D6 metabolizer group",ncit:negative,ncit:quantitative,propafenone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,mexiletine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:0821CFA6-7EE4-4348-88A8-AD97B2D46F12,"In another formal study (n = 8 extensive and n = 7 poor metabolizers of CYP2D6), coadministration of propafenone did not alter the kinetics of mexiletine in the poor CYP2D6 metabolizer group. However, the metabolic clearance of mexiletine in the extensive metabolizer phenotype decreased by about 70% making the poor and extensive metabolizer groups indistinguishable",ncit:positive,ncit:quantitative,mexiletine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,propafenone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:1303548D-21C0-482F-8837-7029768068ED,"Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide",ncit:negative,ncit:quantitative,digoxin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,aliskiren,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:CA614DB9-1DCB-4C71-9356-0AEDC662CC7C,"Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure",ncit:negative,ncit:Qualitative,warfarin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,aliskiren,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:02B3D72E-587C-4868-A824-68B5AECEC549,"Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure",ncit:negative,ncit:Qualitative,aliskiren,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,atenolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:52C3AEDB-DE85-4E13-82B0-9B57FCF26832,"Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure",ncit:negative,ncit:Qualitative,amlodipine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,aliskiren,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:CF34DD75-465E-41D5-A7F1-6B0E257E6D3C,"Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure",ncit:negative,ncit:Qualitative,furosemide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,aliskiren,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:79420EB4-27B3-4F7D-82E3-2BD514EEEBF0,"Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure",ncit:negative,ncit:Qualitative,ramipril,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,aliskiren,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:880F2193-3999-4B43-90B8-0662870E0BA5,"Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide",ncit:negative,ncit:quantitative,lovastatin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,aliskiren,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:A3CFE951-39DF-4590-8308-6FD03E4F28EF,"Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide",ncit:negative,ncit:quantitative,aliskiren,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,atenolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:EF9B6001-45DC-4DE4-91F1-6C4436A057FB,"Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide",ncit:negative,ncit:quantitative,aliskiren,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,ramipril,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:5F01A8CE-2918-4744-90EA-75EB2B818D66,Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren,ncit:positive,ncit:quantitative,ketoconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,aliskiren,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:AD8C6F25-F0D5-4BD6-ABAB-CB90024AE372,"Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide",ncit:negative,ncit:quantitative,amlodipine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,aliskiren,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:8F57DC15-387D-45F1-A0A7-63FF76AFE646,"Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide",ncit:negative,ncit:quantitative,valsartan,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,aliskiren,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:5E0874BC-711D-41AB-8653-5A6F87903470,Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing,ncit:positive,ncit:quantitative,atorvastatin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,aliskiren,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:BBEEF7BD-BD87-403A-B9C2-B526F3D5E7D0,Irbesartan: Coadministration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing,ncit:positive,ncit:quantitative,irbesartan,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,irbesartan,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:BF8BC57B-3F36-4CA8-9FC6-BA3F8F28D0A3,"Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure",ncit:negative,ncit:Qualitative,aliskiren,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,lovastatin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:F7919DE3-9F37-474F-AE39-8F782FB6BEB4,"Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure",ncit:negative,ncit:Qualitative,hydrochlorothiazide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,aliskiren,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:9474141F-5D00-4A10-A377-D1451693CF6C,"Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure",ncit:negative,ncit:Qualitative,metformin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,aliskiren,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:1C04BB76-DCC0-4164-8EF0-8EA160892942,"Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide",ncit:negative,ncit:quantitative,aliskiren,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,celecoxib,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:C62BF5EF-B2CC-453A-8DAB-CCFA8C2F2337,"Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide",ncit:negative,ncit:quantitative,metformin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,aliskiren,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:ED66485F-35D6-476A-9C90-48A8E4FBF678,Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren,ncit:positive,ncit:quantitative,verapamil,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,aliskiren,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:2491FD08-F5AC-449E-B8DA-066B3B8AE2E6,"Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure",ncit:negative,ncit:Qualitative,digoxin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,aliskiren,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:FBB8BB0C-DE78-4567-A198-140FF9407072,"Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure",ncit:negative,ncit:Qualitative,aliskiren,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,celecoxib,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:66BED1D4-F28E-41CC-99BC-BCFCF854385D,"When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively",ncit:positive,ncit:quantitative,aliskiren,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,furosemide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:F3B65A59-0BDD-40E3-8780-5809E3E8FAAD,"Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide",ncit:negative,ncit:quantitative,aliskiren,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,atorvastatin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:3AE1086E-4A19-46FD-8C24-B57B76E07827,"Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide",ncit:negative,ncit:quantitative,aliskiren,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,hydrochlorothiazide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:308E6594-868B-4CD5-BB45-90DF0CB7417E,"Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure",ncit:negative,ncit:Qualitative,aliskiren,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,valsartan,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:A53805E1-2A1D-4E82-BB98-FF194D9AB4B4,Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren,ncit:positive,ncit:quantitative,aliskiren,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,cyclosporine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:448B926C-3B30-4832-99B1-5D459A53B86A,Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren,ncit:positive,ncit:quantitative,aliskiren,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,itraconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:3B4828D5-325E-45ED-B33B-E20AE210FD8A,Sildenafil had no impact on the plasma levels of oral contraceptives (ethinyl estradiol 30 mcg and levonorgestrel 150 mcg),ncit:negative,ncit:quantitative,sildenafil,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,levonorgestrel,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:793074FA-A766-4304-A84E-DF22F70F41D8,Concomitant administration of a single 100 mg dose of sildenafil with 10 mg of atorvastatin did not alter the pharmacokinetics of either sildenafil or atorvastatin,ncit:negative,ncit:quantitative,sildenafil,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,atorvastatin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:BAEC7C92-41EA-4D5C-AF4C-9CC5D2C24495,Concomitant administration of oral contraceptives (ethinyl estradiol 30 mcg and levonorgestrel 150 mcg) did not affect the pharmacokinetics of sildenafil,ncit:negative,ncit:quantitative,ethinyl estradiol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,sildenafil,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:17966803-7253-4754-AA3D-F5DC857C2CBE,Sildenafil had no impact on the plasma levels of oral contraceptives (ethinyl estradiol 30 mcg and levonorgestrel 150 mcg),ncit:negative,ncit:quantitative,sildenafil,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,ethinyl estradiol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:C9741F6F-3DEA-44A5-975A-DB208B3A4A94,Concomitant administration of oral contraceptives (ethinyl estradiol 30 mcg and levonorgestrel 150 mcg) did not affect the pharmacokinetics of sildenafil,ncit:negative,ncit:quantitative,levonorgestrel,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,sildenafil,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:ECBAEBD8-AC10-4705-AB9F-EFA70519EE0D,"When a single 100 mg dose of sildenafil was co-administered with erythromycin, a CYP3A inhibitor, at steady state (500 mg BID for 5 days), there was a 182% increase in sildenafil systemic exposure (AUC)",ncit:positive,ncit:quantitative,erythromycin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,sildenafil,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:E913BDE8-B6A6-427C-A576-AF14FCD9F5B0,"Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol® at steady-state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol® as compared to the same dose of Felbatol® given as monotherapy",ncit:positive,ncit:quantitative,carbamazepine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,Felbatol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:22EB3190-F9B3-4E2D-BBE9-E396AD3E249F,"Phenytoin causes an approximate doubling of the clearance of Felbatol® (felbamate) at steady-state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol® as compared to the same dose of Felbatol® given as monotherapy",ncit:positive,ncit:quantitative,Felbatol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:object-drug-of-interaction,Phenytoin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:37370AFD-44E7-4BBF-801B-D483F2D4E16F,"Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations. In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL. The steady-state Cmin concentration increased to 17.8 micrograms/mL when 2400 mg/day of felbamate was coadministered for one week",ncit:positive,ncit:quantitative,felbamate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,phenobarbital,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:5C88D7FA-91D8-471E-B740-3B837B06E869,"Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations. In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL. The steady-state Cmin concentration increased to 17.8 micrograms/mL when 2400 mg/day of felbamate was coadministered for one week",ncit:positive,ncit:Qualitative,felbamate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,phenobarbital,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:615ED38F-56BF-45DA-ADA6-DABA265D3F45,Results of a placebo-controlled trial in normal volunteers suggest that chronic administration of sertraline 200 mg/day does not produce clinically important inhibition of phenytoin metabolism,ncit:negative,ncit:Qualitative,phenytoin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,sertraline,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:18C15E45-D8FB-4117-B6FB-E13D61374F0C,"In four subjects with epilepsy ingesting valproate, the steady-state trough (Cmin) valproate plasma concentration was 63±16 micrograms/mL. The steady-state Cmin increased to 78±14 micrograms/mL when 1200 mg/day of felbamate was coadministered. Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL. Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively. The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively",ncit:positive,ncit:quantitative,felbamate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,valproate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:BEF178F4-3AA3-4424-8E4F-44908C0A33D0,Valproate: Felbatol® causes an increase in steady-state valproate concentrations,ncit:positive,ncit:Qualitative,valproate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Felbatol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:6B440742-8A62-4585-ABBB-1DF1ACA79A47,Carbamazepine: Felbatol® causes a decrease in the steady-state carbamazepine plasma concentrations and an increase in the steady-state carbamazepine epoxide plasma concentration,ncit:positive,ncit:Qualitative,Felbatol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,carbamazepine epoxide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:0A79131C-EFFB-4374-869D-DBA4D110E846,Carbamazepine: Felbatol® causes a decrease in the steady-state carbamazepine plasma concentrations and an increase in the steady-state carbamazepine epoxide plasma concentration,ncit:positive,ncit:Qualitative,carbamazepine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Felbatol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:5C89BBB9-68A1-4295-9A9A-FADB132370B5,"In nine otherwise healthy subjects with epilepsy ingesting carbamazepine, the steady-state trough (Cmin) carbamazepine concentration was 8±2 micrograms/mL. The carbamazepine steady-state Cmin decreased 31% to 5±1 micrograms/mL when felbamate (3000 mg/day, divided into three doses) was coadministered. Carbamazepine epoxide steady-state Cmin concentrations increased 57% from 1.0±0.3 to 1.6±0.4 micrograms/mL with the addition of felbamate.",ncit:positive,ncit:quantitative,Carbamazepine epoxide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction,felbamate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:1DD1A67E-1FC2-4386-B0C4-977BF12B59A1,"In nine otherwise healthy subjects with epilepsy ingesting carbamazepine, the steady-state trough (Cmin) carbamazepine concentration was 8±2 micrograms/mL. The carbamazepine steady-state Cmin decreased 31% to 5±1 micrograms/mL when felbamate (3000 mg/day, divided into three doses) was coadministered",ncit:positive,ncit:quantitative,felbamate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,carbamazepine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:A8FACCC4-B610-479A-B90D-293A855EF46D,"In 10 otherwise healthy subjects with epilepsy ingesting phenytoin, the steady-state trough (Cmin) phenytoin plasma concentration was 17±5 micrograms/mL. The steady-state Cmin increased to 21±5 micrograms/mL when 1200 mg/day of felbamate was coadministered. Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25±7 micrograms/mL",ncit:positive,ncit:quantitative,felbamate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,phenytoin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:3F3523DB-E687-45E7-97C1-323E49FFFA1C,Phenytoin: Felbatol® causes an increase in steady-state phenytoin plasma concentrations,ncit:positive,ncit:Qualitative,phenytoin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Felbatol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:E8530987-0843-417D-82A1-01B6FFE789EC,"Felbamate treatment resulted in a 42% decrease in the gestodene AUC 0-24, but no clinically relevant effect was observed on the pharmacokinetic parameters of ethinyl estradiol",ncit:positive,ncit:quantitative,Felbamate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,gestodene,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:599C5343-7BFF-4D64-A39C-0D7B407BA486,"Felbamate treatment resulted in a 42% decrease in the gestodene AUC 0-24, but no clinically relevant effect was observed on the pharmacokinetic parameters of ethinyl estradiol",ncit:negative,ncit:Qualitative,ethinyl estradiol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Felbamate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:352E9C94-1219-4644-AAFB-814C95ECD240,Available data suggest that there is no significant effect of valproate on the clearance of Felbatol® at steady-state,ncit:negative,ncit:quantitative,valproate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,Felbatol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:BD6CA8B5-3646-41F9-A561-EB814D42A704,Coadministration of amlodipine besylate with cimetidine did not alter the pharmacokinetics of amlodipine besylate,ncit:negative,ncit:quantitative,cimetidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,amlodipine besylate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:D587B8D6-E33C-4DAA-955A-684D51446196,Coadministration of a magnesium and aluminum hydroxide antacid with a single dose of amlodipine besylate had no significant effect on the pharmacokinetics of amlodipine besylate,ncit:negative,ncit:quantitative,magnesium and aluminum hydroxide antacid,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,amlodipine besylate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:FF782A33-3972-418B-ACA4-A386BF58E233,A single 100 mg dose of sildenafil in subjects with essential hypertension had no effect on the pharmacokinetic parameters of amlodipine besylate,ncit:negative,ncit:quantitative,sildenafil,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,amlodipine besylate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:DA51581E-8695-4523-85DA-B76844E72E8B,Single and multiple 10 mg doses of amlodipine besylate had no significant effect on the pharmacokinetics of ethanol,ncit:negative,ncit:quantitative,ethanol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,amlodipine besylate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:CDAAA734-AD52-49EF-9DC6-39DDFD0D753B,Coadministration of amlodipine besylate with digoxin did not change serum digoxin levels or digoxin renal clearance in normal volunteers,ncit:negative,ncit:quantitative,amlodipine besylate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,digoxin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:169C92C0-3619-4ED5-BE14-1FBE97A98C87,Coadministration of multiple 10 mg doses of amlodipine besylate with 80 mg of atorvastatin resulted in no significant change in the steady-state pharmacokinetic parameters of atorvastatin,ncit:negative,ncit:quantitative,amlodipine besylate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,atorvastatin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:DF19ABF4-6499-4188-932A-71162EF7BF95,"In a controlled study of a single dose (2 mg) of pimozide, 200 mg sertraline (q.d.) co-adminis-tration to steady state was associated with a mean increase in pimozide AUC and C max of about 40%",ncit:positive,ncit:quantitative,pimozide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,sertraline,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:6B720594-9374-402F-BD26-CE5210495B6D,"However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.",ncit:positive,ncit:Qualitative,ketoconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,fexofenadine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:FA2FDDF5-4A40-4942-9068-FEF7AAACD880,"In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion",ncit:positive,ncit:Qualitative,fexofenadine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,erythromycin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:F5C124EB-EEBF-4A33-903D-FC8EA22CFDF5,"In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion",ncit:positive,ncit:quantitative,fexofenadine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,ketoconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:87980244-8A06-49BF-907D-E4625B9414F2,Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole,ncit:negative,ncit:quantitative,Fexofenadine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,ketoconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:23386D2E-8405-413D-89BD-48FE1D3FEE44,"However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects",ncit:positive,ncit:Qualitative,fexofenadine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,erythromycin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:0595393C-C0B5-4BF0-81D7-2E21D569C13D,These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption,ncit:positive,ncit:Qualitative,fexofenadine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,ketoconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:C3A40F06-2382-4658-9290-2867DFD68CC9,Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole,ncit:negative,ncit:quantitative,erythromycin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Fexofenadine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:F0222214-630B-44B1-B336-620E59C15020,"In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%",ncit:positive,ncit:quantitative,fexofenadine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Maalox®1,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:B70B89E2-678F-4456-B860-4DBD05A578A9,These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption,ncit:positive,ncit:Qualitative,fexofenadine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,erythromycin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:61804D06-AD2F-4070-965F-EA5F58753ED1,"Following coadministration of carbamazepine 400 mg/day with trazodone 100 mg to 300 mg daily, carbamazepine reduced plasma concentrations of trazodone (as well as mCPP) by 76 and 60%, respectively, compared to pre-carbamazepine values",ncit:positive,ncit:quantitative,carbamazepine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,trazodone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:73A91AEF-6922-4787-BBDC-55583C1A3620,"The effect of short-term administration of ritonavir (200 mg twice daily, 4 doses) on the pharmacokinetics of a single dose of trazodone (50 mg) has been studied in 10 healthy subjects. The Cmax of trazodone increased by 34%, the AUC increased 2.4 fold, the half-life increased by 2.2 fold, and the clearance decreased by 52%",ncit:positive,ncit:quantitative,ritonavir,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,trazodone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:AD40DD05-E01C-4756-B989-DFA0D0F7467B,Co-administration of chlorpromazine with propranolol resulted in a 70% increase in propranolol plasma level,ncit:positive,ncit:quantitative,chlorpromazine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,propranolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:0F7015B9-9855-4FA6-9581-3B452B7B1941,Co-administration of long-acting propranolol at doses greater than or equal to 160 mg/day resulted in increased thioridazine plasma concentrations ranging from 55% to 369% and increased thioridazine metabolite (mesoridazine) concentrations ranging from 33% to 209%,ncit:positive,ncit:quantitative,propranolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,mesoridazine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:E5191311-1B57-4B5F-87A3-0F518FA3334F,Co-administration of long-acting propranolol at doses greater than or equal to 160 mg/day resulted in increased thioridazine plasma concentrations ranging from 55% to 369% and increased thioridazine metabolite (mesoridazine) concentrations ranging from 33% to 209%,ncit:positive,ncit:quantitative,thioridazine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,propranolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:E5ADB3ED-A2D5-4CC4-A80F-E63884497C3B,Propranolol did not have an effect on the pharmacokinetics of fluvastatin,ncit:negative,ncit:quantitative,Propranolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,fluvastatin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:B70C25AD-2D87-4DA0-8170-8A53746E2BE5,"Co-administration of propranolol with lovastatin or pravastatin, decreased 18% to 23% the AUC of both, but did not alter their pharmacodynamics",ncit:positive,ncit:quantitative,lovastatin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,propranolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:DDBBEA37-216B-4419-B8ED-6D4F2B68FF75,"Co-administration of propranolol with lovastatin or pravastatin, decreased 18% to 23% the AUC of both, but did not alter their pharmacodynamics",ncit:positive,ncit:quantitative,pravastatin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,propranolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:C03AE3FC-B773-49BC-8F54-13580EA0D150,Co-administration of cholestyramine or colestipol with propranolol resulted in up to 50% decrease in propranolol concentrations,ncit:positive,ncit:quantitative,colestipol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,propranolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:55695289-A398-474E-94B8-FAC13C2DBD55,Co-administration of cholestyramine or colestipol with propranolol resulted in up to 50% decrease in propranolol concentrations,ncit:positive,ncit:quantitative,cholestyramine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,propranolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:F9D181B3-3586-4A78-84A8-291F0BD8C0F0,Co-administration of metoclopramide with the long-acting propranolol did not have a significant effect on propranolol’s pharmacokinetics,ncit:negative,ncit:quantitative,metoclopramide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,propranolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:9C6AD5DD-A2D6-4B8D-9A19-A3F0465EFFCC,"In a placebo-controlled trial in normal volunteers, the administration of two doses of sertraline did not significantly alter steady-state lithium levels or the renal clearance of lithium",ncit:negative,ncit:Qualitative,lithium,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,sertraline,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:3EF7A37B-4200-4921-941B-FE2376B5BAB6,"Co-administration of propranolol with cimetidine, a non-specific CYP450 inhibitor, increased propranolol AUC and Cmax by 46% and 35%, respectively",ncit:positive,ncit:quantitative,cimetidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,propranolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:D1D48C32-A72D-4CFB-BA76-3D53D27B260C,Co-administration with aluminum hydroxide gel (1200 mg) may result in a decrease in propranolol concentrations,ncit:positive,ncit:Qualitative,aluminum hydroxide gel,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,propranolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:098DC3B0-880C-4DF3-BD01-903DFC1433A4,"Propranolol can inhibit the metabolism of diazepam, resulting in increased concentrations of diazepam and its metabolites",ncit:positive,ncit:Qualitative,Propranolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,metabolites,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:276593FA-36FC-408E-A175-1481E50AD9BF,"Propranolol can inhibit the metabolism of diazepam, resulting in increased concentrations of diazepam and its metabolites",ncit:positive,ncit:Qualitative,Propranolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,diazepam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:6743166C-4BD9-42E6-81E2-24403003885E,Diazepam does not alter the pharmacokinetics of propranolol.,ncit:negative,ncit:quantitative,propranolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Diazepam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:C28DC645-5397-412F-9F90-68736D0D63E6,Propranolol does not affect the pharmacokinetics of verapamil and norverapamil,ncit:negative,ncit:quantitative,Propranolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,verapamil,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:2AD19C60-ECC4-4332-9A61-B8041D3DB6D5,Propranolol does not affect the pharmacokinetics of verapamil and norverapamil,ncit:negative,ncit:quantitative,Propranolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,norverapamil,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:AF82752A-1F95-4B32-BFAC-5DE881967678,Verapamil does not affect the pharmacokinetics of propranolol,ncit:negative,ncit:quantitative,Verapamil,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,propranolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:CC49F0F6-99BE-46F9-8668-CFE708A6F58A,"The metabolism of propranolol is reduced by co-administration of quinidine, leading to a two-three fold increased blood concentration and greater degrees of clinical beta-blockade.",ncit:positive,ncit:quantitative,propranolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,quinidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:911A7395-19D8-4CCA-9E7A-ACD22183C2DC,The AUC of propafenone is increased by more than 200% by co-administration of propranolol.,ncit:positive,ncit:quantitative,propranolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,propafenone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:C9C95095-5BE6-4232-877D-BBA17074D730,Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone,ncit:negative,ncit:quantitative,rosiglitazone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,metformin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:E30C2104-2771-4A37-9830-399AD5AF42F2,Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA,ncit:negative,ncit:quantitative,glimepiride,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,AVANDIA,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:64ADBA36-93FD-4107-8FAA-98EE66EF8896,Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers,ncit:negative,ncit:quantitative,warfarin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,AVANDIA,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:07245151-36C5-4C3D-9DE7-1CE5C3EC3907,Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone,ncit:negative,ncit:quantitative,metformin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,AVANDIA,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:7F510B2F-FEB2-4251-9BBB-6956B79924D5,"AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), ",ncit:negative,ncit:quantitative,AVANDIA,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,nifedipine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:2B102093-E192-4491-A651-AB4D36BB7B76,Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.,ncit:negative,ncit:quantitative,acarbose,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,AVANDIA,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:06D7E0B3-3876-4EE0-9E56-59896156D3E3,No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects,ncit:negative,ncit:quantitative,AVANDIA,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,glimepiride,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:A100A8DC-0088-4A22-B4F5-4A23A6693CBA,"AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), ",ncit:negative,ncit:quantitative,AVANDIA,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,norethindrone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:669F74AD-DB83-4AB8-A19A-E235B8319B91,"AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), ",ncit:negative,ncit:quantitative,ethinyl estradiol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,AVANDIA,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:C2D0A54B-7D11-43B8-8893-535C72C2E536,"In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.",ncit:positive,ncit:Qualitative,glyburide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,AVANDIA,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:3D8C13BD-29C3-476E-B96F-F0FDD1E65E27,Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.,ncit:positive,ncit:Qualitative,AVANDIA,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,glyburide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:2FFB91FD-54DC-4739-8CAE-80F1F160E010,Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers,ncit:negative,ncit:quantitative,digoxin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,AVANDIA,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:AA6BE552-8318-4FED-A388-966E2AF709DD,Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers,ncit:negative,ncit:quantitative,ranitidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,rosiglitazone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:FDE100C2-06DA-4236-9118-F25D424642FD,"Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.",ncit:positive,ncit:quantitative,rosiglitazone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,gemfibrozil,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:D6A6B68F-1840-46D2-885C-AF4827C4A8EC,"Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone ",ncit:positive,ncit:Qualitative,Rifampin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,rosiglitazone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:C96388C6-5A36-438E-A3AE-9EF4647A40E9,"An inhibitor of CYP2C8 (e.g., gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (e.g., rifampin) may decrease the AUC of rosiglitazone. ",ncit:positive,ncit:Qualitative,rosiglitazone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,rifampin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:C995B594-3E29-42FB-AEDD-5CE072820D85,"An inhibitor of CYP2C8 (e.g., gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (e.g., rifampin) may decrease the AUC of rosiglitazone. ",ncit:positive,ncit:Qualitative,rosiglitazone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,gemfibrozil,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:4dddae9d-17e5-4c15-a650-c472c7493d5b,"In a study comparing the disposition of intravenously administered diazepam before and after 21 days of dosing with either sertraline (50 to 200 mg/day escalating dose) or placebo, there was a 32% decrease relative to baseline in diazepam clearance for the sertraline group compared to a 19% decrease relative to baseline for the placebo group (p < 0.03). There was a 23% increase in T max for desmethyldiazepam in the sertraline group compared to a 20% decrease in the placebo group (p < 0.03). ",ncit:positive,ncit:quantitative,desmethyldiazepam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite,dikbD2R:object-drug-of-interaction,sertraline,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:3414c9fb-9877-47bf-924b-f552583064d8,"In a study comparing the disposition of intravenously administered diazepam before and after 21 days of dosing with either sertraline (50 to 200 mg/day escalating dose) or placebo, there was a 32% decrease relative to baseline in diazepam clearance for the sertraline group compared to a 19% decrease relative to baseline for the placebo group (p < 0.03). ",ncit:positive,ncit:quantitative,sertraline,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,diazepam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:9DD343F7-8674-4195-804A-B0DB1A80DE4B,"Concomitant administration of Synercid and nifedipine (repeated oral doses) and midazolam (intravenous bolus dose) in healthy volunteers led to elevated plasma concentrations of these drugs. The Cmax increased by 18% and 14% (median values) and the AUC increased by 44% and 33% for nifedipine and midazolam, respectively.",ncit:positive,ncit:Qualitative,Synercid,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,nifedipine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:98AABBCE-B4BB-4854-A2A9-77BE066BB57D,"Concomitant administration of Synercid and nifedipine (repeated oral doses) and midazolam (intravenous bolus dose) in healthy volunteers led to elevated plasma concentrations of these drugs. The Cmax increased by 18% and 14% (median values) and the AUC increased by 44% and 33% for nifedipine and midazolam, respectively.",ncit:positive,ncit:Qualitative,Synercid,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,midazolam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:363C1550-8AE2-40A4-95F3-7674878B4C35,Coadministration of rosiglitazone (4 mg b.i.d.) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine,ncit:negative,ncit:quantitative,rosiglitazone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,nifedipine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:69AF8CF9-C065-434B-809D-C9428DA32839,"Coadministration of nifedipine 10 mg capsule and 60 mg nifedipine coat-core tablet with phenytoin, an inducer of CYP3A4, lowered the AUC and Cmax of nifedipine by approximately 70%",ncit:positive,ncit:quantitative,nifedipine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,phenytoin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:46003D55-F5B5-48C8-B425-F01C57250376,"Concomitant administration of quinupristin/dalfopristin and nifedipine (repeated oral dose) in healthy volunteers increased AUC and Cmax for nifedipine by factors of 1.44 and 1.18, respectively, compared to nifedipine monotherapy",ncit:positive,ncit:quantitative,quinupristin/dalfopristin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,nifedipine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:F26711E3-0228-42D2-9C66-DCEBEBAEC754,"In normotensive subjects receiving single doses of 10 mg or multiple doses of up to 20 mg nifedipine t.i.d. alone or together with cimetidine up to 1000 mg/day, the AUC values of nifedipine in the presence of cimetidine were between 1.52 and 2.01 times those in the absence of cimetidine",ncit:positive,ncit:quantitative,nifedipine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,cimetidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:45723BE7-0BAE-4404-83AD-00A4E3232B41,The Cmax values of nifedipine in the presence of cimetidine were increased by factors ranging between 1.60 and 2.02.,ncit:positive,ncit:quantitative,cimetidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,nifedipine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:43E03C75-2A99-433D-A52E-4E8BF3375FF6,"In the presence of doxazosin, AUC and Cmax of nifedipine were increased by factors of 1.13 and 1.23, respectively",ncit:positive,ncit:quantitative,doxazosin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,nifedipine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:6006B9E0-4FC1-44CD-BD5A-7F801160D7C9,"Coadministration of nifedipine resulted in a decrease in AUC and Cmax of doxazosin to 83% and 86% of the values in the absence of nifedipine, respectively",ncit:positive,ncit:quantitative,doxazosin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,nifedipine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:A3872BFD-0F74-4CDC-AAFE-EB8DE673C1BE,"However, in clinical studies, concomitant nifedipine had no effect on irbesartan pharmacokinetics",ncit:negative,ncit:quantitative,irbesartan,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,nifedipine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:CC8737AC-EF42-4606-8445-C5157F08E66C,"Pretreatment of healthy volunteers with 30 mg or 90 mg t.i.d. diltiazem p.o. increased the AUC of nifedipine after a single dose of 20 mg nifedipine by factors of 2.2 and 3.1, respectively. The corresponding Cmax values of nifedipine increased by factors of 2.0 and 1.7, respectively",ncit:positive,ncit:quantitative,diltiazem,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,nifedipine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:6B4FE8E4-2E4E-41F2-A910-ACDA4E8CD8FA,"Coadministration of multiple doses of quinidine sulfate, 200 mg t.i.d., and nifedipine, 20 mg t.i.d., increased Cmax and AUC of nifedipine in healthy volunteers by factors of 2.30 and 1.37, respectively",ncit:positive,ncit:quantitative,quinidine sulfate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,nifedipine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:A603E215-223A-4449-AA61-F25D03A4E9DB,The exposure to quinidine was not importantly changed in the presence of nifedipine,ncit:negative,ncit:Qualitative,quinidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,nifedipine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:C9910A9D-E3A2-42BA-9B1D-590FA2D41347,"Drugs that inhibit CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone are likely to increase metoprolol concentration",ncit:positive,ncit:Qualitative,paroxetine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,metoprolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:86BF4CFD-4ED2-4DF8-A96E-48C321F4BFB0,"In four patients with cardiovascular disease, coadministration of propafenone 150 mg t.i.d. with immediate-release metoprolol 50 mg t.i.d. resulted in two- to five-fold increases in the steady-state concentration of metoprolol",ncit:positive,ncit:quantitative,metoprolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,propafenone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:C5104C66-1212-4DB3-9A1E-6D5DC91CE415,"In healthy subjects with CYP2D6 extensive metabolizer phenotype, coadministration of quinidine 100 mg and immediate-release metoprolol 200 mg tripled the concentration of S-metoprolol and doubled the metoprolol elimination half-life",ncit:positive,ncit:quantitative,metoprolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,quinidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:47EE4B75-B35F-4BAF-A63C-8BB190D33885,"Drugs that inhibit CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone are likely to increase metoprolol concentration",ncit:positive,ncit:Qualitative,metoprolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,propafenone,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:5D2C0767-5EAA-46CD-AF0D-2BA6C3781C27,"Drugs that inhibit CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone are likely to increase metoprolol concentration",ncit:positive,ncit:Qualitative,quinidine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,metoprolol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:507FB160-18FA-45EA-8D09-6D54413D410F,The pharmacokinetics of oral conivaptan (20 - 40 mg/day) were unchanged with coadministration of either captopril 25 mg or furosemide up to 80 mg/day,ncit:negative,ncit:quantitative,conivaptan,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,captopril,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:1B4542B4-6611-4BAE-A15C-7F0EEAD92D91,"VAPRISOL 40 mg/day increased the mean AUC values by approximately 2- and 3-fold for 1 mg intravenous or 2 mg oral doses of midazolam, respectively",ncit:positive,ncit:quantitative,VAPRISOL,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,midazolam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:E53D7999-38C3-4BF6-9D4E-D2410FE87B42,"Coadministration of a 0.5 mg dose of digoxin, a P-glycoprotein substrate, with oral conivaptan hydrochloride 40 mg twice daily resulted in a 30% reduction in clearance and 79% and 43% increases in digoxin Cmax and AUC values, respectively",ncit:positive,ncit:quantitative,digoxin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,conivaptan hydrochloride,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:AA7C38E5-2889-489E-BDEB-199E81FDC705,he pharmacokinetics of oral conivaptan (20 - 40 mg/day) were unchanged with coadministration of either captopril 25 mg or furosemide up to 80 mg/day,ncit:negative,ncit:quantitative,conivaptan,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,furosemide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:1B6E66EA-C64C-407A-9F75-D274E2240DA3,"Coadministration of oral conivaptan hydrochloride 10 mg with ketoconazole 200 mg resulted in 4- and 11-fold increases in Cmax and AUC of conivaptan, respectively",ncit:positive,ncit:quantitative,conivaptan,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,ketoconazole,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:759FDE5C-F679-445B-8093-FC9DE128A5C1,Oral conivaptan hydrochloride 40 mg twice daily resulted in a 2-fold increase in the AUC and half-life of amlodipine,ncit:positive,ncit:quantitative,conivaptan hydrochloride,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,amlodipine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:686AB9C1-7FE2-4BD2-B059-E4E0C0A00AFF,VAPRISOL 30 mg/day resulted in a 3-fold increase in the AUC of simvastatin,ncit:positive,ncit:quantitative,VAPRISOL,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction,simvastatin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:543214C5-0A8A-449D-8B46-823130E062A3,"VAPRISOL (40 mg/day for 4 days) administered with a single 25 mg dose of warfarin, which undergoes major metabolism by CYP2C9 and minor metabolism by CYP3A, increased the mean S-warfarin AUC and S-warfarin Cmax by 14% and 17%, respectively",ncit:positive,ncit:quantitative,warfarin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,VAPRISOL,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:86835822-C5BD-4F47-903F-140D6B8A57CE,"Absorption of drugs from the stomach may be diminished by metoclopramide (e.g., digoxin), whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine)",ncit:positive,ncit:Qualitative,metoclopramide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,acetaminophen,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:0BC57CCC-8FCB-4618-942E-17EBE8C9E7A4,"Absorption of drugs from the stomach may be diminished by metoclopramide (e.g., digoxin), whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine)",ncit:positive,ncit:Qualitative,metoclopramide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,tetracycline,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:865232CE-3FBA-4E2B-B1DE-B2083DCCEAAA,"Absorption of drugs from the stomach may be diminished by metoclopramide (e.g., digoxin),",ncit:positive,ncit:Qualitative,metoclopramide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,digoxin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:B2C70EBB-12FF-41FB-A610-DD83159001B8,"Absorption of drugs from the stomach may be diminished by metoclopramide (e.g., digoxin), whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine)",ncit:positive,ncit:Qualitative,metoclopramide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,cyclosporine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
urn:domeoclient:uuid:6082FF05-47F6-4A72-A5D9-0F64A0B0B3DD,"Absorption of drugs from the stomach may be diminished by metoclopramide (e.g., digoxin), whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine)",ncit:positive,ncit:Qualitative,ethanol,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,metoclopramide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:BCF5B409-C402-40D9-AFE8-72C3759C1A3E,"Because the action of metoclopramide will hasten the movement of food to the intestines and therefore the rate of absorption, insulin dosage or timing of dosage may require adjustment",ncit:positive,ncit:Qualitative,insulin,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,metoclopramide,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:C255D095-3B2B-4F4C-B0CC-942933448A8C,Carbamazepine can increase alprazolam metabolism and therefore can decrease plasma levels of alprazolam,ncit:positive,ncit:Qualitative,alprazolam,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction,Carbamazepine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction
urn:domeoclient:uuid:2AA0AF51-37A5-4350-A6D4-D635B499ABA8,Exposure to didanosine is increased when coadministered with tenofovir disoproxil fumarate ,ncit:positive,ncit:Qualitative,tenofovir disoproxil fumarate,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:precipitant-drug-of-interaction,didanosine,http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient,dikbD2R:object-drug-of-interaction
